



University of Dundee

Genome-wide association meta-analyses combining multiple risk phenotypes provide insights into the genetic architecture of cutaneous melanoma susceptibility

GenoMEL Consortium; Q-MEGA and QTWIN Investigators; ATHENS Melanoma Study Group; 23andMe; The SDH Study Group; IBD Investigators

Published in:
Nature Genetics

DOI:
[10.1038/s41588-020-0611-8](https://doi.org/10.1038/s41588-020-0611-8)

Publication date:
2020

Document Version
Peer reviewed version

[Link to publication in Discovery Research Portal](#)

Citation for published version (APA):

GenoMEL Consortium, Q-MEGA and QTWIN Investigators, ATHENS Melanoma Study Group, 23andMe, The SDH Study Group, IBD Investigators, Essen-Heidelberg Investigators, AMFS Investigators, MelaNostrum Consortium, Landi, M. T., Bishop, D. T., MacGregor, S., Machiela, M. J., Stratigos, A. J., Ghorzo, P., Brossard, M., Calista, D., Choi, J., Fargnoli, M. C., ... Law, M. H. (2020). Genome-wide association meta-analyses combining multiple risk phenotypes provide insights into the genetic architecture of cutaneous melanoma susceptibility. *Nature Genetics*, 52(5), 494-504. <https://doi.org/10.1038/s41588-020-0611-8>

General rights

Copyright and moral rights for the publications made accessible in Discovery Research Portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from Discovery Research Portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain.
- You may freely distribute the URL identifying the publication in the public portal.

Take down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

Genome-wide association meta-analyses combining multiple risk phenotypes provides insights into the genetic architecture of cutaneous melanoma susceptibility

Maria Teresa Landi^{1,*,@}, D. Timothy Bishop^{2,*}, Stuart MacGregor^{3,*}, Mitchell J. Machiela^{1,*}, Alexander J. Stratigos^{4,#}, Paola Ghiorzo^{5,#}, Myriam Brossard⁶, Donato Calista⁷, Jiyeon Choi¹, Maria Concetta Fagnoli⁸, Tongwu Zhang¹, Monica Rodolfo⁹, Adam J. Trower¹⁰, Chiara Menin¹¹, Jacobo Martinez¹², Andreas Hadjisavvas¹³, Lei Song¹, Irene Stefanaki¹⁴, Richard Scolyer^{15,16,17,18}, Rose Yang¹, Alisa M. Goldstein¹, Miriam Potrony¹⁹, Katerina P. Kypreou¹⁴, Lorenza Pastorino²⁰, Paola Queirolo²¹, Cristina Pellegrini⁸, Laura Cattaneo²², Matthew Zawistowski²³, Pol Gimenez-Xavier¹⁹, Arantxa Rodriguez²⁴, Lisa Elefanti¹¹, Siranoush Manoukian²⁵, Licia Rivoltini⁹, Blair H. Smith²⁶, Maria A. Loizidou¹³, Laura Del Regno^{27,28}, Daniela Massi²⁹, Mario Mandala³⁰, Kiarash Khosrotehrani^{31,32}, Lars A. Akslen^{33,34}, Christopher I. Amos³⁵, Per A. Andresen³⁶, Marie-Françoise Avril³⁷, Esther Azizi^{38,39}, H. Peter Soyer^{40,32}, Veronique Bataille⁴¹, Bruna Dalmasso^{5,42}, Lisa M. Bowdler⁴³, Kathryn P. Burdon⁴⁴, Wei V. Chen⁴⁵, Veryan Codd^{46,47}, Jamie E. Craig⁴⁸, Tadeusz Dębniak⁴⁹, Mario Falchi⁴¹, Shenyang Fang⁵⁰, Eitan Friedman³⁹, Sarah Simi²⁹, Pilar Galan⁵¹, Zaida Garcia-Casado²⁴, Elizabeth M. Gillanders⁵², Scott Gordon⁵³, Adele Green^{54,55}, Nelleke A. Gruis⁵⁶, Johan Hansson⁵⁷, Mark Harland⁵⁸, Jessica Harris⁵⁹, Per Helsing⁶⁰, Anjali Henders⁶¹, Marko Hočevár⁶², Veronica Höiom⁵⁷, David Hunter^{63,64}, Christian Ingvar⁶⁵, Rajiv Kumar⁶⁶, Julie Lang⁶⁷, G. Mark Lathrop⁶⁸, Jeffrey E. Lee⁵⁰, Xin Li⁶⁹, Jan Lubiński⁷⁰, Rona M. Mackie^{71,67}, Maryrose Malt⁵⁴, Josep Malvehy⁷², Kerrie McAloney⁵³, Hamida Mohamdi⁶, Anders Molven^{34,73}, Eric K. Moses⁷⁴, Rachel E. Neale⁷⁵, Srdjan Novaković⁷⁶, Dale R. Nyholt^{77,53}, Håkan Olsson^{78,79}, Nicholas Orr⁸⁰, Lars G. Fritsche⁸¹, Joan Anton Puig-Butille⁸², Abrar A. Qureshi⁸³, Graham L. Radford-Smith^{84,85,86}, Juliette Randerson-Moor⁵⁸, Celia Requena²⁴, Casey Rowe³¹, Nilesh J. Samani^{46,47}, Marianna Sanna⁴¹, Dirk Schadendorf^{87,88}, Hans-Joachim Schulze⁸⁹, Lisa A. Simms⁸⁴, Mark Smithers^{90,91}, Fengju Song⁹², Anthony J. Swerdlow^{93,94}, Nienke van der Stoep⁹⁵, Nicole A. Kukutsch⁵⁶, Alessia Visconti⁴¹, Leanne Wallace⁶¹, Sarah V. Ward^{96,97}, Lawrie Wheeler⁵⁹, Richard A. Sturm⁴⁰, Amy Hutchinson^{1,98}, Kristine Jones^{1,98}, Michael Malasky^{1,98}, Aurelie Vogt^{1,98}, Weiyin Zhou^{1,98}, Karen A. Pooley⁹⁹, David E. Elder¹⁰⁰, Jiali Han⁶⁹, Belynda Hicks^{1,98}, Nicholas K. Hayward¹⁰¹, Peter A. Kanetsky¹⁰², Chad Brummett¹⁰³, Grant W. Montgomery¹⁰⁴, Catherine M Olsen¹⁰⁵, Caroline Hayward¹⁰⁶, Alison M. Dunning¹⁰⁷, Nicholas G. Martin⁵³, Evangelos Evangelou^{108,109}, Graham J. Mann¹¹⁰, Georgina Long^{15,111}, Paul D. P. Pharoah¹⁰⁷, Douglas F. Easton⁹⁹, Jennifer H. Barrett¹⁰, Anne E. Cust^{110,112}, Goncalo Abecasis¹¹³, David L. Duffy^{53,114}, David C. Whiteman¹⁰⁵, Helen Gogas¹¹⁵, Arcangela De Nicolo¹¹⁶, Margaret A. Tucker¹, Julia A. Newton Bishop⁵⁸, GenoMEL Consortium¹¹⁷, Q-MEGA and QTWIN Investigators¹¹⁷, ATHENS Melanoma Study Group¹¹⁷, 23andMe¹¹⁷, The SDH Study Group¹¹⁷, IBD Investigators¹¹⁷, Essen-Heidelberg Investigators¹¹⁷, AMFS Investigators¹¹⁷, MelaNostrum Consortium¹¹⁷, Ketty Peris^{27,28}, Stephen J. Chanock¹, Florence Demenais⁶, Kevin M. Brown^{1,#}, Susana Puig^{19,#}, Eduardo Nagore^{24,#}, Jianxin Shi^{1,*}, Mark M. Iles^{10,*,@}, Matthew H. Law^{3,*,@}

¹Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA

²Leeds Institute of Medical Research at St James's, University of Leeds, Leeds, UK & Leeds Institute for Data Analytics, University of Leeds, Leeds, UK

³Statistical Genetics, QIMR Berghofer Medical Research Institute, Brisbane, Australia

⁴Department of Dermatology, Andreas Syggros Hospital, Medical School, National and Kapodistrian University of Athens, Athens, Greece

⁵Genetics of Rare Cancers, Department of Internal Medicine (DiMI), University of Genoa and Ospedale Policlinico San Martino Genoa, Genoa, Italy

⁶Institut National de la Santé et de la Recherche Médicale (INSERM), UMRS-1124, Genetic Epidemiology and Functional Genomics of Multifactorial Diseases Team, Université Paris Descartes, Paris, France

⁷Department of Dermatology, Maurizio Bufalini Hospital, Cesena, Italy

⁸Department of Dermatology, Department of Biotechnological and Applied Clinical Sciences, University of L'Aquila, L'Aquila, Italy

⁹Unit of Immunotherapy of Human Tumors, Department of Research, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Italy

¹⁰Leeds Institute for Data Analytics, University of Leeds, Leeds, UK

- ¹¹Immunology and Molecular Oncology Unit, Veneto Institute of Oncology IOV - IRCCS, Padua, Italy
- ¹²Red Valenciana de Biobancos, FISABIO
- ¹³Department of EM/Molecular Pathology & The Cyprus School of Molecular Medicine, The Cyprus Institute of Neurology and Genetics, Nicosia, Cyprus
- ¹⁴Department of Dermatology, University of Athens School of Medicine, Andreas Sygros Hospital, Athens, Greece
- ¹⁵Melanoma Institute Australia, The University of Sydney, Sydney, Australia
- ¹⁶Royal Prince Alfred Hospital, Sydney, NSW, Australia
- ¹⁷The University of Sydney, Central Clinical School, Sydney, NSW, Australia
- ¹⁸New South Wales Health Pathology, Sydney, NSW, Australia
- ¹⁹Dermatology Department, Melanoma Unit, Hospital Clinic de Barcelona, IDIBAPS, Universitat de Barcelona, Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), Barcelona, Spain
- ²⁰Genetics of Rare Cancers, Department of Internal Medicine (DiMI), University of Genoa and Policlinico San Martino Research Hospital Genoa, Genoa, Italy
- ²¹Medical Oncology, Ospedale Policlinico San Martino Genoa, Genoa, Italy
- ²²Pathology Unit, Azienda Socio-Sanitaria Territoriale Papa Giovanni XXIII, Bergamo, Italy
- ²³Department of Biostatistics, University of Michigan School of Public Health, Ann Arbor, MI 48109, USA; Center for Statistical Genetics, University of Michigan School of Public Health, Ann Arbor, MI 48109, US
- ²⁴Department of Dermatology, Instituto Valenciano de Oncología, València, Spain
- ²⁵Unit of Medical Genetics, Department of Medical Oncology and Hematology, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Italy
- ²⁶Division of Population Health and Genomics, Ninewells Hospital and Medical School, University of Dundee, Dundee DD1 9SY, United Kingdom
- ²⁷Institute of Dermatology, Catholic University, Rome, Italy
- ²⁸Fondazione Policlinico Universitario A. Gemelli, IRCCS-Rome, Italy
- ²⁹Section of Anatomic Pathology, Department of Health Sciences, University of Florence, Italy
- ³⁰Department of Oncology, Giovanni XXIII Hospital, Bergamo, Italy
- ³¹The University of Queensland, UQ Diamantina Institute, Brisbane Australia
- ³²Department of Dermatology, Princess Alexandra Hospital, Brisbane, Australia
- ³³Centre for Cancer Biomarkers CCBIO, Department of Clinical Medicine, University of Bergen, Bergen, Norway
- ³⁴Department of Pathology, Haukeland University Hospital, Bergen, Norway
- ³⁵Department of Community and Family Medicine, Geisel School of Medicine, Dartmouth College, Hanover, New Hampshire, USA
- ³⁶Department of Pathology, Molecular Pathology, Oslo University Hospital, Rikshospitalet, Oslo, Norway
- ³⁷Assistance Publique-Hôpitaux de Paris, Hôpital Cochin, Service de Dermatologie, Université Paris Descartes, Paris, France
- ³⁸Department of Dermatology, Sheba Medical Center, Tel Hashomer, Sackler Faculty of Medicine, Tel Aviv, Israel
- ³⁹Oncogenetics Unit, Sheba Medical Center, Tel Hashomer, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
- ⁴⁰Dermatology Research Centre, The University of Queensland Diamantina Institute, Translational Research Institute, Brisbane, Qld 4102, Australia
- ⁴¹Department of Twin Research and Genetic Epidemiology, King's College London, London, SE1 7EH, UK Plus, for Veronique: Department of Dermatology, West Herts NHS Trust, Herts, HP2 4AD, UK
- ⁴²Laboratory of Genetics of Rare Cancers, Istituto di ricovero e cura a carattere scientifico Azienda Ospedaliera Universitaria (IRCCS AOU) San Martino-IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy
- ⁴³Sample Processing, QIMR Berghofer Medical Research Institute, Brisbane, Australia
- ⁴⁴Menzies Institute for Medical Research, University of Tasmania, Hobart, Tasmania, Australia
- ⁴⁵Department of Genetics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
- ⁴⁶Department of Cardiovascular Sciences, University of Leicester, Leicester, UK
- ⁴⁷NIHR Leicester Biomedical Research Centre, Glenfield Hospital, Leicester, UK
- ⁴⁸Department of Ophthalmology, Flinders University, Adelaide, Australia
- ⁴⁹Department of Genetics and Pathology, International Hereditary Cancer Center, Pomeranian Medical University, Szczecin, Poland
- ⁵⁰Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
- ⁵¹Université Paris 13, Equipe de Recherche en Epidémiologie Nutritionnelle (EREN), Centre de Recherche en Epidémiologie et Statistiques, Institut National de la Santé et de la Recherche Médicale (INSERM U1153), Institut National de la Recherche Agronomique (INRA U1125), Conservatoire National des Arts et Métiers, Communauté d'Université Sorbonne Paris Cité, F-93017 Bobigny, France
- ⁵²Inherited Disease Research Branch, National Human Genome Research Institute, National Institutes of Health, Baltimore, Maryland, USA
- ⁵³Genetic Epidemiology, QIMR Berghofer Medical Research Institute, Brisbane, Australia
- ⁵⁴Cancer and Population Studies, QIMR Berghofer Medical Research Institute, Brisbane, Australia
- ⁵⁵CRUK Manchester Institute and Institute of Inflammation and Repair, University of Manchester, Manchester, UK
- ⁵⁶Department of Dermatology, Leiden University Medical Centre, Leiden, The Netherlands

- ⁵⁷Department of Oncology-Pathology, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden
- ⁵⁸Leeds Institute of Medical Research at St James's, University of Leeds, Leeds, UK
- ⁵⁹Translational Research Institute, Institute of Health and Biomedical Innovation, Princess Alexandra Hospital, Queensland University of Technology, Brisbane, Australia
- ⁶⁰Department of Dermatology, Oslo University Hospital, Rikshospitalet, Oslo, Norway
- ⁶¹Institute for Molecular Bioscience, The University of Queensland, Brisbane, Australia.
- ⁶²Department of Surgical Oncology, Institute of Oncology Ljubljana, Ljubljana, Slovenia
- ⁶³University of Oxford, Nuffield Department of Population Health, Oxford, UK
- ⁶⁴Harvard T.H. Chan School of Public Health, Program in Genetic Epidemiology and Statistical Genetics, Boston, MA, USA
- ⁶⁵Department of Surgery, Clinical Sciences, Lund University, Lund, Sweden
- ⁶⁶Division of Molecular Genetic Epidemiology, German Cancer Research Center, Im Neuenheimer Feld 580, Heidelberg Germany
- ⁶⁷Department of Medical Genetics, University of Glasgow, Glasgow, UK
- ⁶⁸McGill University and Genome Quebec Innovation Centre, Montreal, Canada
- ⁶⁹Department of Epidemiology, Richard M. Fairbanks School of Public Health, Melvin and Bren Simon Cancer Center, Indiana University, Indianapolis, USA
- ⁷⁰International Hereditary Cancer Center, Pomeranian Medical University, Szczecin, Poland
- ⁷¹Department of Public Health, University of Glasgow, Glasgow UK
- ⁷²Dermatology Department, Melanoma Unit, Hospital Clínic de Barcelona, IDIBAPS, Universitat de Barcelona, Centro de Investigación Biomédica en Red en Enfermedades Raras (CIBERER), Barcelona, Spain
- ⁷³Gade Laboratory for Pathology, Department of Clinical Medicine, University of Bergen, Bergen, Norway
- ⁷⁴Centre for Genetic Origins of Health and Disease, Faculty of Medicine, Dentistry and Health Sciences, The University of Western Australia, Western Australia, Australia
- ⁷⁵Cancer Aetiology & Prevention, QIMR Berghofer Medical Research Institute, Brisbane, Australia
- ⁷⁶Department of Molecular Diagnostics, Institute of Oncology Ljubljana, Ljubljana, Slovenia
- ⁷⁷School of Biomedical Sciences and Institute of Health and Biomedical Innovation, Queensland University of Technology, Brisbane, Queensland, Australia
- ⁷⁸Department of Oncology/Pathology, Clinical Sciences, Lund University, Lund; Sweden
- ⁷⁹Department of Cancer Epidemiology, Clinical Sciences, Lund University, Lund, Sweden
- ⁸⁰Breakthrough Breast Cancer Research Centre, The Institute of Cancer Research, London, UK
- ⁸¹Center for Statistical Genetics, Department of Biostatistics, University of Michigan School of Public Health, Ann Arbor, MI, USA
- ⁸²Biochemistry and Molecular Genetics Department, Melanoma Unit, Hospital Clínic de Barcelona, IDIBAPS, Universitat de Barcelona, Centro de Investigación Biomédica en Red en Enfermedades Raras (CIBERER), Barcelona, Spain
- ⁸³Department of Dermatology, The Warren Alpert Medical School of Brown University, Rhode Island, USA
- ⁸⁴Inflammatory Bowel Diseases, QIMR Berghofer Medical Research Institute, Brisbane, Australia
- ⁸⁵Department of Gastroenterology and Hepatology, Royal Brisbane & Women's Hospital, Brisbane, Australia
- ⁸⁶University of Queensland School of Medicine, Herston Campus, Brisbane, Australia
- ⁸⁷Department of Dermatology, University Hospital Essen, Essen, Germany
- ⁸⁸German Consortium Translational Cancer Research (DKTK), Heidelberg, Germany
- ⁸⁹Department of Dermatology, Fachklinik Hornheide, Institute for Tumors of the Skin at the University of Münster, Münster, Germany
- ⁹⁰Queensland Melanoma Project, Princess Alexandra Hospital, The University of Queensland, Australia
- ⁹¹Mater Research Institute, The University of Queensland, Australia.
- ⁹²Departments of Epidemiology and Biostatistics, Key Laboratory of Cancer Prevention and Therapy, Tianjin, National Clinical Research Center of Cancer, Tianjin Medical University Cancer Institute and Hospital, Tianjin, P. R. China
- ⁹³Division of Genetics and Epidemiology, The Institute of Cancer Research, London, UK
- ⁹⁴Division of Breast Cancer Research, The Institute of Cancer Research, London, UK
- ⁹⁵Department of Clinical Genetics, Center of Human and Clinical Genetics, Leiden University Medical Center, Leiden, The Netherlands
- ⁹⁶Centre for Genetic Origins of Health and Disease, School of Biomedical Sciences, The University of Western Australia, Perth, Australia
- ⁹⁷Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York, USA
- ⁹⁸Cancer Genome Research Laboratory, Leidos Biomedical Research Inc., Bethesda, Maryland, USA
- ⁹⁹Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK
- ¹⁰⁰Department of Pathology and Laboratory Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania, USA
- ¹⁰¹Oncogenomics, QIMR Berghofer Medical Research Institute, Brisbane, Australia
- ¹⁰²Department of Cancer Epidemiology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, USA
- ¹⁰³Department of Anesthesiology, University of Michigan, Ann Arbor, MI, USA

¹⁰⁴Molecular Biology, the University of Queensland, Brisbane, Australia.

¹⁰⁵Cancer Control Group, QIMR Berghofer Medical Research Institute, Brisbane, Australia

¹⁰⁶MRC Human Genetics Unit, Institute of Genetics and Molecular Medicine, University of Edinburgh, Western General Hospital, Edinburgh EH42 XU, United Kingdom

¹⁰⁷Centre for Cancer Genetic Epidemiology, Department of Oncology, University of Cambridge, Cambridge, UK

¹⁰⁸Department of Hygiene and Epidemiology, University of Ioannina Medical School, Ioannina, Greece

¹⁰⁹Department of Epidemiology and Biostatistics, Imperial College London, London, UK

¹¹⁰Centre for Cancer Research, Westmead Institute for Medical Research, and The Melanoma Institute, The University of Sydney, Sydney, Australia

¹¹¹Royal North Shore Hospital, Sydney Australia

¹¹²Cancer Epidemiology and Prevention Research, Sydney School of Public Health, and The Melanoma Institute, University of Sydney, Sydney, Australia

¹¹³Department of Biostatistics, University of Michigan, Ann Arbor, 48109, MI, USA

¹¹⁴The University of Queensland Diamantina Institute, The University of Queensland, Woolloongabba, QLD 4102, Australia

¹¹⁵First Department of Internal Medicine, Laikon General Hospital Greece, National and Kapodistrian University of Athens, Athens, Greece

¹¹⁶Cancer Genomics Program, Veneto Institute of Oncology IOV - IRCCS, Padua, Italy

¹¹⁷A full list of members and affiliations appears in the Supplementary Note

*Jointly supervised this work

#Contributed equally

@Corresponding authors: Mark M. Iles, Matthew H. Law, Maria Teresa Landi

Abstract

Most genetic susceptibility to cutaneous melanoma (CM) remains to be discovered. Meta-analysis genome-wide association study (GWAS) of 36,760 melanoma cases (67% newly-genotyped) and 375,188 controls identified 54 significant loci with 68 independent SNPs. Analysis of risk estimates across geographical regions and host factors suggests the acral melanoma subtype is uniquely unrelated to pigmentation. Combining this meta-analysis with nevus count and hair colour GWAS, and transcriptome association approaches, uncovered 31 potential secondary loci, for a total of 85 CM susceptibility loci. These findings provide substantial insights into CM genetic architecture, reinforcing the importance of neovogenesis, pigmentation, and telomere maintenance together with identifying potential new pathways for CM pathogenesis.

Cutaneous melanoma (CM) is a deadly malignancy with increasing incidence and burden in fair-skinned populations worldwide¹. Increased risk for CM is caused by high exposure to ultraviolet radiation², as well as host factors including family history^{3,4}, pigmentary phenotypes⁵, number of melanocytic nevi^{6,7}, longer telomeres^{8,9}, and immunosuppression¹⁰.

Identified melanoma genetic risk variants include rare, highly penetrant mutations in genes such as *CDKN2A*^{11,12} and *POT1*^{13,14}, as well as more common variants (e.g., lower-penetrance variants in *MC1R*)^{15,16}. Genome-wide association studies (GWAS) of CM susceptibility in populations of European ancestry have identified 21 genetic loci reaching genome-wide significance ($P < 5 \times 10^{-8}$)¹⁷⁻²⁴. Additional approaches, including family-based analyses of CM^{25,26}, combining CM and nevus count GWAS²⁷ and transcriptome-wide association studies (TWAS)²⁸ have identified further loci that, despite not containing SNPs reaching $P < 5 \times 10^{-8}$ in a CM-only GWAS, most likely influence melanoma risk.

This meta-analysis of CM susceptibility is more than three times the effective sample size of previous CM GWAS, providing unprecedented power to identify CM susceptibility variants and enhanced distinction of independent variants in known CM susceptibility regions. We report here 68 independent CM associated variants across 54 loci that confirm the importance of key functional pathways and highlight previously unknown CM etiologic routes (**Tables 1-2**). Stratified analyses revealed a lack of involvement of the pigmentation pathway for acral melanoma, in line with observational data²⁹. The combined analysis of CM, nevus and hair colour GWAS data, and use of expression data through TWAS, revealed 31 secondary, potential loci.

Results

Study overview

We performed a GWAS meta-analysis of CM susceptibility with 30,134 clinically-confirmed CM cases (**Online Methods**), 6,626 self-reported CM cases and 375,188 CM-free controls from the United Kingdom, United States, Australia, Northern and Western Europe as well as the Mediterranean – a highly sun exposed population often under-represented in CM studies (**Supplementary Table 1**). Of these, 24,756 cases (67%) and 358,734 controls (96%) had not been included in any previous melanoma GWAS.

Separately, we performed total (clinically confirmed cases + self-reported cases from 23andMe, Inc. and a subset of UK Biobank cases with only self-reported CM status) and confirmed-only CM meta-analyses to determine the power gained by including self-reported CM cases. Risk loci were deemed genome-wide significant when variants had fixed effects meta-analysis P-values $< 5 \times 10^{-8}$ (P_{meta}); where variants exhibited notable heterogeneity ($I^2 > 31\%$)³⁰ random effects P-values (P_{meta_r}) were also required to be $< 5 \times 10^{-8}$ (**Online Methods**). Q-Q plots (**Supplementary Figure 1**) and LD score regression³¹ (LDSC; **Online Methods**) intercepts showed minimal inflation for individual studies (mostly < 1.04 ; **Supplementary Table 1**), indicating adequate control of population stratification.

Before including the self-report GWAS data, we used LDSC³¹ to verify their genetic correlation (R_g) with the confirmed-only GWAS meta-analysis (**Supplementary Note; Supplementary Table 2**). Based on the high R_g and similarity in h^2 estimates for self-report and clinically confirmed CM cases (**Supplementary Note**), we performed an overall total CM meta-analysis ($h^2_{\text{total}} = 0.11$, 95% CI=0.08-0.15). The lambda and LDSC intercept for the total CM meta-analysis indicated that the majority of inflation is due to polygenic signal ($\lambda = 1.165$, intercept=1.054, ratio=0.17;

Supplementary Table 2). A similar h^2_{total} (12%) was estimated using genetic effect-size distribution inference from summary level data (GENESIS; **Online Methods**)³².

Conditional and joint analysis of the total CM meta-analysis summary statistics using GCTA³³ identified a total of 54 loci meeting our requirements for genome-wide significance (**Online Methods**; **Figure 1, Extended Data Figures 1-2**). Results for loci previously reported by CM GWAS reaching significance in the total meta-analysis are presented in **Table 1**. Results for loci not previously reported by a CM GWAS are summarised in **Table 2**. In addition to the 54 lead variants, 14 independent variants with linkage disequilibrium (LD) $r^2_{\text{EUR}} < 0.05$ with lead variants at or near 6 loci (*TERT*, *AGR3*, *CDKN2A*, *OCA2*, *MC1R*, and *TP53*) were identified (**Supplementary Table 3**). Individual regional association plots for the association signals have been provided as a **Supplementary Dataset 1**. Conditional and joint analysis of summary data identified a further 9 variants at or near *SLC45A2*, *IRF4*, *AGR3*, *CCND1*, *GPRC5A*, *FTO*, and *MC1R*; however, these additional variants were not carried forward, having either $P_{\text{meta}} > 5 \times 10^{-8}$ in the single variant analysis or excess heterogeneity ($I^2 > 31\%$) and $P_{\text{meta}_r} < 5 \times 10^{-8}$ (**Supplementary Table 4**). In addition, we used GENESIS (**Online Methods**), which enables a reformulation of the variance explained by associated SNPs to estimate a theoretical optimal area under the curve (AUC), rather than formally testing this using a training and prediction set³² to estimate the potential AUC. The estimated AUC was 66.8%, compared to ~64% in the 2015 CM meta-analysis²³. This estimate does not include any host factors and would require benchmarking in a prospective study for validation.

Previous CM GWAS have identified 21 genome-wide significant loci¹⁷⁻²⁴. Family-based methods or the combination of CM with nevus count have identified a further 12 loci including *IRF4*, *MITF*, *HDAC4*, and *GPRC5A*^{25-27,34,35}. The lead SNPs from many of these loci are associated with pigmentation, tanning response, nevus count, and telomere maintenance (**Supplementary Table 5**). Other SNPs are proximal to DNA repair genes. Some loci are associated with more than one trait (**Tables 1-2**). Our analysis confirms 19 of the 21 loci previously reaching genome-wide significance (**Table 1**; **Supplementary Note**). The total CM meta-analysis also confirms the previously reported *IRF4* and *MITF* associations^{25-27,34,35}, as well as 6 regions previously identified only by combining nevus count and CM GWAS data²⁷ (**Table 2**; **Supplementary Note**). These results demonstrate the ability of cross-trait GWAS to identify disease loci. The remaining 27 loci have not previously been reported as CM susceptibility loci (**Table 2**; **Supplementary Table 3**). The results for the pathologically confirmed-only CM cases (N=30,134; **Supplementary Table 1, Extended Data Figure 2-3**) are reported in the **Supplementary Note**. Our full meta-analysis identified 11 loci not found in the confirmed-only GWAS meta-analysis, demonstrating the advantage of including the 6,626 self-reported CM cases and over 290,000 controls (**Supplementary Table 1**). Results for SNPs with a fixed or random $P < 5 \times 10^{-7}$, from the total meta-analysis are reported in **Supplementary Table 7**.

Melanoma associations by sex, age at diagnosis and subtype

We performed separate GWAS by sex, age at CM diagnosis (≤ 40 , 40-60, ≥ 60 years) and major CM subtypes (superficial spreading (SS), lentigo maligna (LM), nodular melanoma (NM), and acral lentiginous (AL)) to identify variants associated with select subgroups (**Supplementary Table 8**). Our analysis identified no additional variants after adjustment for multiple testing ($5 \times 10^{-8}/9$), suggesting that if such variants exist they are undetectable at our current sample size.

We also performed polygenic risk score (PRS) analyses based on the lead independent genome-wide significant SNPs for nevus count (10 variants; **Online Methods**) and hair colour (276 variants; **Online Methods**) to explore further whether either trait's association with CM differs across phenotypic subtypes (significance threshold=0.05/28; **Online Methods**). We observed no significant differences in the distribution of the tested PRSs by sex or age at CM diagnosis. We did,

however, detect differences in the distribution of the hair colour PRS for the acral lentiginous subtype compared to all non-acral subtypes ($P=2.1 \times 10^{-4}$). Our analyses indicated that genetically-predicted pigmentation in AL cases was no different to controls ($P=0.65$, **Extended Data Figure 4**) and darker than in SS, LM and NM cases ($P=5.3 \times 10^{-5}$, 0.01, 4.8×10^{-4} , respectively). These findings provide strong genetic evidence that the pigmentation pathway is far less important for risk of AL melanoma than for other subtypes of CM. No significant differences were observed by subtype for the nevus count PRS.

Variant annotation using CM risk phenotypes

To investigate possible biological pathways underlying CM signals, variants independently associated with CM in the total meta-analysis were evaluated in GWAS of telomere length, tanning response, pigmentation and nevus count (**Online Methods, Table 1 and 2, Supplementary Tables 5,7-8**). Using a Bonferroni-corrected threshold of phenotype P-value <0.00074 ($0.05/68$ independent SNPs), 18 of the 35 novel loci are associated with tanning response or pigmentation (**Table 2, Supplementary Table 5**), further indicating the importance of pigmentation pathways in CM susceptibility. Several new loci, including rs12473635 near *DTNB* and rs78378222 near *TP53*, are associated with nevus count, reinforcing the role of nevi in CM susceptibility. Furthermore, four novel loci have previously been associated with telomere length (rs3950296/*TERC*, rs4731207/*POT1*, rs2967383/*MPHOSPH6*, and rs143190905/*RTEL1*³⁶) (**Table 2, Supplementary Table 5**) providing additional support for the role of telomere maintenance in CM susceptibility following earlier findings that genetic determinants of telomere length are generally associated with melanoma risk^{13,14,37}. Other newly-discovered lead variants are not associated with these phenotypes, suggesting novel pathways.

Utilising additional approaches to identify CM risk loci

To identify further loci influencing CM risk and provide a more nuanced annotation of discovered CM risk loci, we used a range of secondary approaches with correction for multiple testing (**Online Methods**). To explore the overlap between CM loci and established risk factor phenotypes, we combined our total CM GWAS meta-analysis with a nevus count GWAS meta-analysis ($N=65,777$; **Online Methods**) and separately with a UKBB hair colour GWAS ($N=352,662$; **Online Methods**). For the total CM GWAS meta-analysis and nevus count the R_g is 0.57 ($SE=0.11$, $P\text{-value}=2.39 \times 10^7$), and for hair colour scored from light hair to dark (**Online Methods**) the R_g is 0.290 ($SE=0.096$, $P\text{-value}=0.0025$). Pairwise GWAS (GWAS-PW)³⁸ was used to determine whether loci were associated with only one trait or pleiotropic with both CM and either nevus count or hair colour (**Online Methods**). Loci previously-reported through the combination of CM and nevus GWAS²⁷ are now confirmed by our larger CM GWAS meta-analysis (**Table 2**). Together these analyses identified secondary potential loci not associated at genome-wide significance levels in the total CM GWAS meta-analysis. At the Bonferroni-corrected threshold of 1.25×10^{-8} (**Online Methods**), they included 8 loci jointly significant for CM and nevus count, 17 for CM and hair colour, and 4 with CM, nevus count and hair colour (**Table 3, Supplementary Table 9, Supplementary Table 10**).

In parallel, we examined data from a recently-established cell-type specific melanocyte *cis*-eQTL dataset²⁸ as well as tissue-based *cis*-eQTL datasets available through GTEx³⁹ to identify additional susceptibility loci using a transcriptome prediction mapping strategy (or transcriptome-wide association study; TWAS)^{40,41}. TWAS utilising these expression datasets enabled gene-based testing for significant *cis* genetic correlations between imputed gene expression and CM risk, aiding identification of additional susceptibility loci (**Online Methods**). While identification of significant genes by TWAS does not establish causation, it can indicate plausible gene candidates to be utilized

in pathway analyses and investigated in future functional studies. This analysis built on a previous melanocyte TWAS that analyzed data from a prior CM GWAS meta-analysis²⁸ and identified significant novel associations between CM and imputed gene expression of five genes at four loci. Importantly, the *CBWD1* locus on chromosome 9 was later identified as a genome-wide significant CM+nevus count pleiotropic locus²⁷ (**Table 3, Supplementary Table 9**), and the other three loci (*ZFP90* on chromosome 16, *HEBP1* on chromosome 12, and *MSC/RP11-383H13.1* on chromosome 8) are now at genome-wide significance with CM in this larger GWAS meta-analysis (**Table 2**). This confirmation supports the TWAS approach for both identifying new loci and nominating potentially functional genes at GWAS-discovered loci (**Tables 1-2**).

To empirically identify the target tissues for CM risk variants, we used partitioned LD score regression⁴² to determine the proportion of total CM GWAS meta-analysis heritability that could be captured by genes expressed in melanocytes and in 50 GTEx tissue types. We found that partitioned CM heritability was most enriched in genes specifically expressed in melanocytes (2.76-fold, $P=3.12 \times 10^{-6}$ for top 4,000 genes; **Extended Data Figure 5**), followed by three other skin-related tissues (GTEx sun-exposed and non-sun-exposed skin, transformed skin fibroblasts). This enrichment was much stronger than the one based on the previously published melanoma GWAS²³. We then focused on these four tissues for discovery of new loci, applying Bonferroni correction for multiple comparisons based on the number of genes tested within each tissue set (**Online Methods**). TWAS using the melanocyte dataset (**Supplementary Table 11, Supplementary Table 3**) identified a total of 40 significant genes. Combining genes within 1 Mb of each other into discrete loci, 32 genes were located within 13 formally genome-wide significant CM GWAS loci, and eight genes were identified within six novel loci. Considering the other skin-related tissues collectively (**Supplementary Table 12, Supplementary Table 3**), TWAS identified a single significant gene at one additional novel locus, as well as genes within 15 GWAS-significant loci. The TWAS using all GTEx tissues is reported in **Supplementary Table 13**.

In aggregate, these complementary approaches identified a total of 85 discrete loci (**Figure 2; Supplementary Table 14**): 54 formally significant at $P < 5 \times 10^{-8}$ in the total CM meta-analysis (**Table 1, Table 2, Supplementary Table 3**), and the remainder supported by one or more of the secondary analyses (**Table 3-5, Supplementary Tables 7-10, 14**) and likely representing additional CM risk loci, but requiring a larger sample size to reach genome-wide significance. In order to annotate CM GWAS loci for candidate susceptibility genes for pathway analyses as well as future functional studies, we turned to eQTL colocalization analyses. These approaches identified multiple pathways that may play a role in developing melanoma and are described in the **Supplementary Note**.

Discussion

We report the largest CM GWAS meta-analysis to date with over three times the effective sample size of prior analyses (**Supplementary Table 1**). We identified 68 independent CM-associated variants across 54 loci. TWAS analysis, eQTL colocalization and multi-marker genomic annotations, identified promising gene candidates at many of these risk loci. Joint pairwise GWAS with the CM-related traits of nevus count and hair colour, and TWAS identified a further 31 independent loci that, while not formally reaching genome-wide significance for CM alone, represent potential additional risk loci. Our CM meta-analysis also confirmed several loci previously identified only by TWAS²⁸, supporting the value of TWAS in identifying additional genes associated with CM (**Table 4**). In total, our integrative analysis of CM susceptibility identified 85 loci associated with CM susceptibility (**Tables 1-4, Figure 2**), constituting a substantial increase from the 21 loci previously identified by CM susceptibility GWAS alone

(**Table 1**), in addition to those found by family-based approaches or in combination with nevus GWAS data (**Table 2**).

Our analyses showed strong genetic correlation between self-reported and clinically-confirmed cases (**Supplementary Table 2; Supplementary Note**), and inclusion of self-reported cases enabled the identification of 11 additional CM susceptibility loci (**Supplementary Tables 3,6; Supplementary Note**), indicating that self-reported CM cases are a valuable and reliable resource for genomic CM studies. Furthermore, we assessed CM genetic susceptibility across several geographic regions, including the often-underrepresented Mediterranean population. Interestingly, we found little evidence for difference in CM locus effect estimates by contributing GWAS (**Supplementary Figure 2**) or differences in effect size and allele frequency by geographic regions (**Supplementary Figure 3**), beyond minor variation in pigmentation genes (e.g., rs6059655 near *ASIP* and rs1805007 near *MC1R*). The stratified analysis based on CM histological subtypes identified acral lentiginous melanomas as being uniquely unassociated with pigmentation loci, in line with observational data²⁹. In contrast, the stratified analyses based on age at diagnosis and gender found no evidence for differences in the distribution of nevus-related or pigmentation-related loci.

The discovery of new loci and genes augments our understanding of CM risk and provides many new insights into CM etiology. Many of the loci previously associated with nevus count²⁷ or pigmentation⁵⁷ are also associated with CM (**Table 2**) confirming the close relationship between these traits. Specifically, of 10 loci previously significantly-associated in a joint analysis of CM and Nevus, but not associated with CM alone²⁷, 6 are now associated with CM alone (**Table 2**), demonstrating the benefits of conducting joint analyses. The remaining 4 loci reach $P < 5 \times 10^{-8}$ in the joint CM+Nevus analysis (**Supplementary Table 9**); 3 of which are significant at the Bonferroni corrected threshold of 1.25×10^{-8} (**Table 3**). In turn, we conducted further pleiotropic analyses and identified secondary loci associated with a combination of both these traits and CM, but not significantly associated with CM alone (**Table 3**). Loci found in such joint analyses are of value as they would likely be associated with CM alone in a sufficiently large CM GWAS meta-analysis. These joint analyses provide a direct biological interpretation that several GWAS risk loci may act through nevus development, in line with clinical evidence. Interestingly, following these expanded pleiotropic analyses, many loci were associated with neither nevus count or hair colour, indicating that many risk variants act outside of these classic CM risk phenotypes (**Tables 1-2**).

The discovery of many new loci, when added to the existing catalog of melanoma risk loci, augments our understanding of the genetic architecture of CM, as discussed in the **Supplementary Note**. It is important to note that confirmation of the genes we have identified are causal for CM, and the biological understanding of how variants at these loci influence CM, remains to be functionally established. For example, melanocyte eQTL and TWAS analyses indicated *PARP1* expression was associated with CM risk SNPs at 1q42^{28,58}. While *PARP1* is an established DNA repair gene, extensive functional characterization of the CM risk locus over *PARP1* demonstrated that its role in CM appears to be through regulation of melanocyte proliferation, senescence, and transcriptional regulation of the key melanoma oncogene *MITF*⁵⁸. Despite the need for follow-up functional studies, a preliminary, complex model of pathways potentially important for the development of melanoma is emerging through the candidate genes suggested by this and prior work, including pathways mediating protection against UV-induced DNA damage and DNA repair, telomere maintenance, immunity, melanocyte differentiation, and cell adhesion.

For example, we identified an association between multiple independent variants at the *TP53* locus, rs78378222 and rs1641548, and CM further reinforcing the potential importance of DNA repair and genome integrity for CM susceptibility (see **Supplementary Note**). Rare germline mutations in *TP53* lead to Li-Fraumeni syndrome⁵⁹ which is associated with early onset of cancer, including

CM⁶⁰. Notably, one of the common sequence variants we found to be associated with CM has previously been shown to alter *TP53* mRNA levels by disruption of *TP53* polyadenylation. *TP53* responds to cellular stresses to regulate target gene expression resulting in DNA repair, cell cycle arrest, apoptosis, and cellular senescence^{61,62}; variation resulting in loss of normal TP53 function could result in clonal expansion of cells that carry accumulated mutations, which may explain the association with both CM and nevus count.

This study also adds to a growing body of evidence supporting a key role for telomere maintenance in CM susceptibility^{8,9,13,14,37,51,63}, with CM risk loci associated with telomere length or located near prominent telomere maintenance genes or loci, including *POT1*, *TERC*, *RTEL1*, *MPHOSPH6*, and *OBFC1*. Additional previously-identified GWAS loci are located near *CCND1* (rs4354713), *ATM* (rs1801516), and *PARP1* (rs2695237), all genes with established roles in telomere maintenance, DNA repair, and regulation of senescence^{64,65}.

The well-established role of immunity in melanoma biology has fueled a search for an association between variation within the HLA region and melanoma risk⁶⁶⁻⁶⁸. While several studies have investigated associations between HLA alleles and CM, these studies have largely been conducted on small, underpowered datasets and have not been consistently replicated⁶⁹⁻⁷⁹. Here, we report identification of a genome-wide significant association between CM susceptibility and rs28986343 at the HLA locus (see **Supplementary Note**). This additional evidence for a role for immunity adds to previous²⁸ and current TWAS and colocalization analyses suggesting association between rs408825 and expression of the innate immunity gene *MX2*. Additionally, many risk alleles for the autoimmune melanocyte-related disorder vitiligo^{48,80} are protective for CM with the lead SNPs either identical (rs1126809/*TYR*; rs6059655/*ASIP*), or in strong LD with CM lead SNPs (rs251464 near *PPARGC1B* for vitiligo, rs32578 for melanoma, LD $r^2_{EUR}=0.73$; rs72928038 near *BACH2* for vitiligo, rs6908626 for melanoma, $r^2_{EUR}=0.95$; rs1129038 near *OCA2* for vitiligo, rs12913832 for melanoma, $r^2_{EUR}=0.99$). While the vitiligo and CM associations share many similar loci, suggesting a role for immunity, we cannot rule out their action on CM risk being through pigmentation or protection against UV damage. Taken as a whole, these data suggest further investigation into these potentially immune-related associations, and more broadly the role of immunity in melanoma risk.

New loci emerging from these analyses suggest a role of genes or networks regulating the development and differentiation of the melanocytic lineage. The CM meta-analysis identified a locus near *FOXD3*, while the pleiotropic CM+Nevus analysis and TWAS locus identified a novel locus significantly associated with allelic expression of *NOTCH2* in melanocytes (**Supplementary Note**). *FOXD3* participates as a part of a larger gene regulatory network governing the development of melanocytes from the neural crest, at least in part through transcriptional repression of one of the earliest markers of melanoblast development (and melanoma predisposition gene), *MITF*^{81,82}. *NOTCH2*, as well as *NOTCH1*, appear to play roles in both development of the melanocyte lineage as well as maintenance of melanocyte stem cells^{53,83}, and NOTCH signaling has been shown to lead to de-differentiation of melanocytes to multipotent neural crest stem-like cells⁸⁴. These two new candidate susceptibility genes join previously-identified loci also harboring genes involved in melanocyte fate. Whole-genome and targeted sequencing studies of melanoma-prone families led to the identification of a functional intermediate-penetrance missense mutation of *MITF* associated with both melanoma and nevus count (*MITF* p.E318K)^{25,26}, a variant that was rediscovered by this population-based meta-analysis (rs149617956, $P=5.17 \times 10^{-25}$, OR=0.38). Additionally, a previously-identified melanoma and nevus risk locus⁸⁵ is located ~200kb from *SOX10*, another key regulator of melanocyte development and differentiation and direct transcriptional activator of *MITF*. These genes, and others in this gene regulatory network, have likewise been variously implicated in the progression of melanoma⁸⁶⁻⁹⁰.

The identification of a CM risk locus for which risk genotype strongly correlates with higher melanocyte-specific expression of *CDH1*, encoding E-cadherin, suggests a potential role for cell-cell adhesion in melanoma risk (see **Supplementary Note**). E-cadherin plays a crucial role in cell-cell adhesion, epithelial-mesenchymal transition (EMT) and carcinoma progression. Germline mutations in this gene are associated with a variety of tumors including gastric⁹¹, breast⁹², and potentially colorectal cancer⁹³. In human skin, E-cadherin is typically expressed on the cell surface of both melanocytes and keratinocytes and is considered the major adhesion molecule between these two cell types^{54,55}. During melanoma progression, expression of E-cadherin is typically lost, with a concurrent switch to expression of N-cadherin, facilitating preferential association with fibroblasts and vascular endothelial cells⁵⁵. In contrast to loss of E-cadherin expression with melanoma progression, we find the CM risk allele at this locus to be associated with higher expression of *CDH1*. Interestingly, melanocytes in non-lesional skin of vitiligo patients have been found to have loss of or discontinuously distributed E-cadherin expression. This loss of E-cadherin induces reduced adhesiveness to the basal layer under oxidative and mechanical stress, leading melanocytes to migrate passively to the exterior of the skin, and die by apoptosis⁹⁴. Thus, germline variation leading to higher melanocyte *CDH1* could act as a protective mechanism, allowing cells damaged by oxidative stress to remain in the skin and survive without dying. A similar mechanism has been recently identified in breast cancer metastasis, where E-cadherin acts as a survival factor by limiting reactive oxygen-mediated apoptosis⁹⁵.

In summary, our large, international genetic meta-analysis showcases the utility of including self-reported CM cases, complementary analytical approaches, and data from multiple sources to expand our understanding of CM risk. While the biological mechanisms underlying many of the existing and novel CM risk loci remain to be confirmed or discovered by post-GWAS functional studies and even larger GWAS, these data suggest potential pathways novel to melanoma susceptibility, and highlight nevus formation, pigmentation and telomere maintenance, the three pathways that appear to dominate the landscape of melanoma susceptibility.

Acknowledgments

NCI

This study was supported by the Intramural Research Program of the Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Department of Health and Human Services.

AOCS/OCAC/SEARCH

AOCS/OCAC/SEARCH is accessible via European Genome-Phenome Archive. We acknowledge their support and data, and the contribution of the study nurses, research assistants and all clinical and scientific collaborators in generation of these data. We also acknowledge their funding sources; OCAC (NIH U19CA148112), SEARCH team (Cancer Research UK C490/A16561), AOCS (U.S. Army Medical Research and Materiel Command under DAMD17-01-1-0729, The Cancer Council Victoria, Queensland Cancer Fund, The Cancer Council New South Wales, The Cancer Council South Australia, The Cancer Foundation of Western Australia, The Cancer Council Tasmania and the NHMRC (ID400413 and ID400281, as well as support from S. Boldeman, the Agar family, Ovarian Cancer Action (UK), Ovarian Cancer Australia and the Peter MacCallum Foundation).

MelaNostrum Consortium

We thank the participants of the MelaNostrum Consortium from Italy (Genoa, L'Aquila, Rome, Padua, Milan, Florence, Bergamo), Spain (Valencia, Barcelona), Greece (Athens), and Cyprus (Nicosia) who provided data and biospecimens for this study. The Consortium is partially supported by the Intramural Research Program of the Division of Cancer Epidemiology and Genetics, NCI, NIH, DHHS. Funding for the University of Genoa and Genetics of Rare Cancers, Ospedale Policlinico San Martino: Italian Ministry of Health 5x1000 per la Ricerca Corrente to Ospedale Policlinico San Martino and AIRC IG 15460. The research at the Melanoma Unit in Barcelona: The Spanish Fondo de Investigaciones Sanitarias grants PI15/00716 and PI15/00956 co-financed by FEDER "Una manera de hacer Europa"; CIBER de Enfermedades Raras of the Instituto de Salud Carlos III, Spain, co-financed by European Development Regional Fund "A way to achieve Europe" ERDF; AGAUR 2014_SGR_603 of the Catalan Government, Spain; European Commission, Contract No. LSHC-CT-2006-018702 (GenoMEL) and by the European Commission under the 7th Framework Programme, Diagnostics; "Fundació La Marató de TV3" 201331-30, Catalonia, Spain; "Fundación Científica de la Asociación Española Contra el Cáncer" GCB15152978SOEN, Spain, and CERCA Programme/Generalitat de Catalunya. Melanoma research at the Department of Dermatology, University of L'Aquila, Italy: Italian Ministry of the University and Scientific Research (PRIN-2012 grant 2012JJX494).

Q-MEGA/QTWIN

The Q-MEGA/QTWIN study was supported by the Melanoma Research Alliance, the NIH NCI (CA88363, CA83115, CA122838, CA87969, CA055075, CA100264, CA133996 and CA49449), the National Health and Medical Research Council of Australia (NHMRC) (200071, 241944, 339462, 380385, 389927, 389875, 389891, 389892, 389938, 443036, 442915, 442981, 496610, 496675, 496739, 552485, 552498, APP1049894), the Cancer Councils New South Wales, Victoria and Queensland, the Cancer Institute New South Wales, the Cooperative Research Centre for Discovery of Genes for Common Human Diseases (CRC), Cerylid Biosciences (Melbourne), the Australian Cancer Research Foundation, The Wellcome Trust (WT084766/Z/08/Z) and donations from Neville and Shirley Hawkins. Stuart MacGregor acknowledges fellowship support from the Australian National Health and Medical Research Council and from the Australian Research Council.

Please see the **Supplementary Note** for additional acknowledgments.

Author Contributions

MTL, MMI, MHL- Project conceptualization and design

DTB, SM, MTL, SJC - Funding support

MTL, DTB, SM, MJM, SJ, MMI, MHL - Results interpretation and study supervision

MJM, MTL, MMI, KB, JC, MHL - Manuscript writing

JS, MMI, KB, TZ, JC, DLD, MHL - Data analyses

AJS, PG, SP, EN - Study coordination and data collection

MTL, DTB, SM, MJM, AJS, PG, MB, DC, JC, MCF, TZ, MR, AJT, CM, JM, AH, LS, IS, RS, RY, AMG, MP, KPK, LP, PQ, CP, LC, MZ, PG2, AR, LE, SM2, LR, BHS, MAL, LDR, DM, MM, KK, LAA, CIA, PAA, MA, EA, HPS, VB, BD, LMB, KPB, WVC, VC, JEC, TD, MF, SF, EF, SS, PG3, ZG, EMG, SG, AG, NAG, JH2, MH, JH3, PH, AH2, MH2, VH, DH, CI, RK, JL, GML, JEL, XL, JL2, RMM, MM2, JM2, KM, HM, AM, EKM, REN, SN, DRN, HO, NO, LGF, JAP, AAQ, GLR, JR, CR, CR2, NJS, MS, DS, HS, LAS, MS2, FS, AJS2, NVDS, NAK, AV, LW, SVW, LW2, RAS, AH3, KJ, MM3, AV2, WZ, KAP, DEE, JH, BH, NKH, PAK, CB, GWM, CMO, CH, AMD, NGM, EE, GJM, GL, PDPP, DFE, JHB, AEC, GA, DLD, DCW, HG, ADN, MAT, JANB, KP, SJC, KMB, FD, SP, EN, JS, MMI, MHL - Participated in data collection, results interpretation and manuscript review

References

1. Karimkhani, C. *et al.* The global burden of melanoma: results from the Global Burden of Disease Study 2015. *British Journal of Dermatology* **177**, 134-140 (2017).
2. Secretan, B. *et al.* WHO International Agency for Research on Cancer Monograph Working Group A review of human carcinogens—Part E: tobacco, areca nut, alcohol, coal smoke, and salted fish. *Lancet Oncol.* **10**, 1033-1034 (2009).
3. Ford, D. *et al.* Risk of cutaneous melanoma associated with a family history of the disease. *Int. J. Cancer* **62**, 377-381 (1995).
4. Olsen, C.M., Carroll, H.J. & Whiteman, D.C. Familial melanoma: a meta-analysis and estimates of attributable fraction. *Cancer Epidemiol. Biomarkers Prev.* **19**, 65-73 (2010).
5. Olsen, C.M., Carroll, H.J. & Whiteman, D.C. Estimating the attributable fraction for melanoma: a meta-analysis of pigmentary characteristics and freckling. *Int. J. Cancer* **127**, 2430-2445 (2010).
6. Chang, Y.M. *et al.* A pooled analysis of Melanocytic nevus phenotype and the risk of cutaneous melanoma at different latitudes. *International Journal of Cancer* (2009).
7. Olsen, C.M., Carroll, H.J. & Whiteman, D.C. Estimating the attributable fraction for cancer: A meta-analysis of nevi and melanoma. *Cancer Prev. Res.* **3**, 233-245 (2010).
8. Bataille, V. *et al.* Nevus size and number are associated with telomere length and represent potential markers of a decreased senescence in vivo. *Cancer Epidemiol. Biomarkers Prev.* (2007).
9. Han, J. *et al.* A prospective study of telomere length and the risk of skin cancer. *J. Invest. Dermatol.* (2009).
10. Green, A.C. & Olsen, C.M. Increased risk of melanoma in organ transplant recipients: systematic review and meta-analysis of cohort studies. *Acta Derm. Venereol.* **95**, 923-927 (2015).
11. Kamb, A. *et al.* Analysis of the p16 gene (CDKN2) as a candidate for the chromosome 9p melanoma susceptibility locus. *Nat. Genet.* **8**, 23-26 (1994).
12. Berwick, M. *et al.* The prevalence of CDKN2A germ-line mutations and relative risk for cutaneous malignant melanoma: an international population-based study. *Cancer Epidemiol. Biomarkers Prev.* **15**, 1520-1525 (2006).
13. Robles-Espinoza, C.D. *et al.* POT1 loss-of-function variants predispose to familial melanoma. *Nat. Genet.* (2014).
14. Shi, J. *et al.* Rare missense variants in POT1 predispose to familial cutaneous malignant melanoma. *Nat. Genet.* **46**, 482-486 (2014).
15. Palmer, J.S. *et al.* Melanocortin-1 receptor polymorphisms and risk of melanoma: is the association explained solely by pigmentation phenotype? *Am. J. Hum. Genet.* **66**, 176-186 (2000).
16. Landi, M.T. *et al.* MC1R, ASIP, and DNA repair in sporadic and familial melanoma in a mediterranean population. *J. Natl. Cancer Inst.* (2005).
17. Brown, K.M. *et al.* Common sequence variants on 20q11.22 confer melanoma susceptibility. *Nat. Genet.* **40**, 838-840 (2008).
18. Bishop, D.T. *et al.* Genome-wide association study identifies three loci associated with melanoma risk. *Nat. Genet.* (2009).
19. Amos, C.I. *et al.* Genome-wide association study identifies novel loci predisposing to cutaneous melanoma. *Hum. Mol. Genet.* **20**, 5012-5023 (2011).
20. Barrett, J.H. *et al.* Genome-wide association study identifies three new melanoma susceptibility loci. *Nat. Genet.* (2011).
21. Macgregor, S. *et al.* Genome-wide association study identifies a new melanoma susceptibility locus at 1q21.3. *Nat. Genet.* **43**, 1114-1118 (2011).
22. Iles, M.M. *et al.* A variant in FTO shows association with melanoma risk not due to BMI. *Nat. Genet.* **45**, 428-32, 432e1 (2013).

23. Law, M.H. *et al.* Genome-wide meta-analysis identifies five new susceptibility loci for cutaneous malignant melanoma. *Nat. Genet.* (2015).
24. Ransohoff, K.J. *et al.* Two-stage genome-wide association study identifies a novel susceptibility locus associated with melanoma. *Oncotarget* **8**, 17586-17592 (2017).
25. Yokoyama, S. *et al.* A novel recurrent mutation in MITF predisposes to familial and sporadic melanoma. (2011).
26. Bertolotto, C. *et al.* A SUMOylation-defective MITF germline mutation predisposes to melanoma and renal carcinoma. *Nature* **480**, 94-98 (2011).
27. Duffy, D.L. *et al.* Novel pleiotropic risk loci for melanoma and nevus density implicate multiple biological pathways. *Nat. Commun.* **9**, 4774 (2018).
28. Zhang, T. *et al.* Cell-type-specific eQTL of primary melanocytes facilitates identification of melanoma susceptibility genes. *Genome Res.* **28**, 1621-1635 (2018).
29. Elder, D.E., Massi, D., Willemze, R. & Scolyer, R. *WHO Classification of Skin Tumours*, 500 (International Agency for Research on Cancer, 2018).
30. Higgins, J.P.T. & Thompson, S.G. Quantifying heterogeneity in a meta-analysis. *Stat. Med.* (2002).
31. Bulik-Sullivan, B. *et al.* An atlas of genetic correlations across human diseases and traits. *Nat. Genet.* (2015).
32. Zhang, Y., Qi, G., Park, J.-H. & Chatterjee, N. Estimation of complex effect-size distributions using summary-level statistics from genome-wide association studies across 32 complex traits. *Nat. Genet.* **50**, 1318-1326 (2018).
33. Yang, J. *et al.* Conditional and joint multiple-SNP analysis of GWAS summary statistics identifies additional variants influencing complex traits. *Nat. Genet.* (2012).
34. Duffy, D.L. *et al.* Multiple Pigmentation Gene Polymorphisms Account for a Substantial Proportion of Risk of Cutaneous Malignant Melanoma. *J. Invest. Dermatol.* **130**, 520-528 (2010).
35. Duffy, D.L. *et al.* IRF4 variants have age-specific effects on nevus count and predispose to melanoma. *Am. J. Hum. Genet.* (2010).
36. Delgado, D.A. *et al.* Genome-wide association study of telomere length among South Asians identifies a second RTEL1 association signal. *J. Med. Genet.* **55**, 64-71 (2018).
37. Iles, M.M. *et al.* The effect on melanoma risk of genes previously associated with telomere length. *J. Natl. Cancer Inst.* **106**(2014).
38. Pickrell, J.K. *et al.* Detection and interpretation of shared genetic influences on 42 human traits. *Nat. Genet.* **48**, 709-717 (2016).
39. Consortium, G.T. Human genomics. The Genotype-Tissue Expression (GTEx) pilot analysis: multitissue gene regulation in humans. *Science* **348**, 648-660 (2015).
40. Gamazon, E.R. *et al.* A gene-based association method for mapping traits using reference transcriptome data. *Nat. Genet.* **47**, 1091-1098 (2015).
41. Gusev, A. *et al.* Integrative approaches for large-scale transcriptome-wide association studies. *Nat. Genet.* **48**, 245-252 (2016).
42. Finucane, H.K. *et al.* Partitioning heritability by functional annotation using genome-wide association summary statistics. *Nat. Genet.* **47**, 1228-1235 (2015).
43. Hormozdiari, F. *et al.* Colocalization of GWAS and eQTL Signals Detects Target Genes. *Am. J. Hum. Genet.* **99**, 1245-1260 (2016).
44. Stacey, S.N. *et al.* A germline variant in the TP53 polyadenylation signal confers cancer susceptibility. *Nat. Genet.* **43**, 1098-1103 (2011).
45. Chahal, H.S. *et al.* Genome-wide association study identifies 14 novel risk alleles associated with basal cell carcinoma. *Nat. Commun.* **7**, 12510 (2016).
46. Ostrom, Q.T. *et al.* Sex-specific glioma genome-wide association study identifies new risk locus at 3p21.31 in females, and finds sex-differences in risk at 8q24.21. *Sci. Rep.* **8**, 7352 (2018).

47. Melin, B.S. *et al.* Genome-wide association study of glioma subtypes identifies specific differences in genetic susceptibility to glioblastoma and non-glioblastoma tumors. *Nat. Genet.* **49**, 789-794 (2017).
48. Jin, Y. *et al.* Genome-wide association studies of autoimmune vitiligo identify 23 new risk loci and highlight key pathways and regulatory variants. *Nat. Genet.* (2016).
49. Zhou, Y., Wu, H., Zhao, M., Chang, C. & Lu, Q. The Bach Family of Transcription Factors: A Comprehensive Review. *Clin. Rev. Allergy Immunol.* **50**, 345-356 (2016).
50. Milovic-Holm, K., Kriehoff, E., Jensen, K., Will, H. & Hofmann, T.G. FLASH links the CD95 signaling pathway to the cell nucleus and nuclear bodies. *EMBO J.* **26**, 391-401 (2007).
51. Aoude, L.G. *et al.* Nonsense mutations in the shelterin complex genes ACD and TERF2IP in familial melanoma. *J. Natl. Cancer Inst.* **107**(2015).
52. Rafnar, T. *et al.* Sequence variants at the TERT-CLPTM1L locus associate with many cancer types. *Nat. Genet.* **41**, 221-227 (2009).
53. Kumano, K. *et al.* Both Notch1 and Notch2 contribute to the regulation of melanocyte homeostasis. *Pigment Cell Melanoma Res.* **21**, 70-78 (2008).
54. Tang, A. *et al.* E-cadherin is the major mediator of human melanocyte adhesion to keratinocytes in vitro. *J. Cell Sci.* **107 (Pt 4)**, 983-992 (1994).
55. Hsu, M.Y., Wheelock, M.J., Johnson, K.R. & Herlyn, M. Shifts in cadherin profiles between human normal melanocytes and melanomas. *J. Investig. Dermatol. Symp. Proc.* **1**, 188-194 (1996).
56. Study, C. *et al.* Meta-analysis of genome-wide association data identifies four new susceptibility loci for colorectal cancer. *Nat. Genet.* **40**, 1426-1435 (2008).
57. Visconti, A. *et al.* Genome-wide association study in 176,678 Europeans reveals genetic loci for tanning response to sun exposure. *Nat. Commun.* **9**, 1684 (2018).
58. Choi, J. *et al.* A common intronic variant of PARP1 confers melanoma risk and mediates melanocyte growth via regulation of MITF. *Nat. Genet.* **49**, 1326-1335 (2017).
59. Li, F.P. & Fraumeni, J.F., Jr. Soft-tissue sarcomas, breast cancer, and other neoplasms. A familial syndrome? *Ann. Intern. Med.* **71**, 747-752 (1969).
60. Curiel-Lewandrowski, C., Speetzen, L.S., Cranmer, L., Warneke, J.A. & Loescher, L.J. Multiple primary cutaneous melanomas in Li-Fraumeni syndrome. *Arch. Dermatol.* **147**, 248-250 (2011).
61. Beausejour, C.M. Reversal of human cellular senescence: roles of the p53 and p16 pathways. *The EMBO Journal* **22**, 4212-4222 (2003).
62. Kuilman, T., Michaloglou, C., Mooi, W.J. & Peeper, D.S. The essence of senescence. *Genes Dev.* **24**, 2463-2479 (2010).
63. Rachakonda, S. *et al.* Telomere length, telomerase reverse transcriptase promoter mutations, and melanoma risk. *Genes Chromosomes Cancer* (2018).
64. Choi, J. *et al.* A common intronic variant of PARP1 confers melanoma risk and mediates melanocyte growth via regulation of MITF. *Nat. Genet.* **49**(2017).
65. Derheimer, F.A. & Kastan, M.B. Multiple roles of ATM in monitoring and maintaining DNA integrity. *FEBS Lett.* **584**, 3675-3681 (2010).
66. Demenais, F. *et al.* A linkage study between HLA and cutaneous malignant melanoma or precursor lesions or both. *J. Med. Genet.* **21**, 429-435 (1984).
67. Bale, S.J. *et al.* Hereditary malignant melanoma is not linked to the HLA complex on chromosome 6. *Int. J. Cancer* **36**, 439-443 (1985).
68. Holland, E.A., Beaton, S.C., Kefford, R.F. & Mann, G.J. Linkage analysis of familial melanoma and chromosome 6 in 14 Australian kindreds. *Genes Chromosomes Cancer* **19**, 241-249 (1997).
69. Barger, B.O., Acton, R.T., Soong, S.J., Roseman, J. & Balch, C. Increase of HLA-DR4 in melanoma patients from Alabama. *Cancer Res.* **42**, 4276-4279 (1982).

70. Rovini, D., Sacchini, V., Codazzi, V., Vaglini, M. & Illeni, M.T. HLA antigen frequencies in malignant melanoma patients. A second study. *Tumori* **70**, 29-33 (1984).
71. Hors, J. *et al.* HLA and Familial Malignant Melanoma. *Histocompatibility Testing 1984*, 407-410 (1984).
72. Lee, J.E., Reveille, J.D., Ross, M.I. & Platsoucas, C.D. HLA-DQB1* 0301 association with increased cutaneous melanoma risk. *International journal of cancer* **59**, 510-513 (1994).
73. Muto, M. *et al.* HLA class I polymorphism and the susceptibility to malignant melanoma. *Tissue Antigens* **47**, 447-449 (1996).
74. Kageshita, T. *et al.* Molecular genetic analysis of HLA class II alleles in Japanese patients with melanoma. *Tissue Antigens* **49**, 466-470 (1997).
75. Bateman, A.C., Turner, S.J., Theaker, J.M. & Howell, W.M. HLA-DQB1*0303 and *0301 alleles influence susceptibility to and prognosis in cutaneous malignant melanoma in the British Caucasian population. *Tissue Antigens* **52**, 67-73 (1998).
76. Lombardi, M.L. *et al.* Molecular analysis of HLA DRB1 and DQB1 polymorphism in Italian melanoma patients. *J. Immunother.* **21**, 435-439 (1998).
77. Luongo, V. *et al.* HLA allele frequency and clinical outcome in Italian patients with cutaneous melanoma. *Tissue Antigens* **64**, 84-87 (2004).
78. Campillo, J.A. *et al.* HLA class I and class II frequencies in patients with cutaneous malignant melanoma from southeastern Spain: the role of HLA-C in disease prognosis. *Immunogenetics* **57**, 926-933 (2006).
79. Planelles, D. *et al.* HLA class II polymorphisms in Spanish melanoma patients: homozygosity for HLA-DQA1 locus can be a potential melanoma risk factor. *Br. J. Dermatol.* **154**, 261-266 (2006).
80. Jin, Y. *et al.* Genome-wide association analyses identify 13 new susceptibility loci for generalized vitiligo. *Nat. Genet.* **44**, 676-680 (2012).
81. Curran, K. *et al.* Interplay between Foxd3 and Mitf regulates cell fate plasticity in the zebrafish neural crest. *Dev. Biol.* **344**, 107-118 (2010).
82. Thomas, A.J. & Erickson, C.A. FOXD3 regulates the lineage switch between neural crest-derived glial cells and pigment cells by repressing MITF through a non-canonical mechanism. *Development* **136**, 1849-1858 (2009).
83. Schouwey, K., Larue, L., Radtke, F., Delmas, V. & Beermann, F. Transgenic expression of Notch in melanocytes demonstrates RBP-Jkappa-dependent signaling. *Pigment Cell Melanoma Res.* **23**, 134-136 (2010).
84. Zabierowski, S.E. *et al.* Direct reprogramming of melanocytes to neural crest stem-like cells by one defined factor. *Stem Cells* **29**, 1752-1762 (2011).
85. Falchi, M. *et al.* Genome-wide association study identifies variants at 9p21 and 22q13 associated with development of cutaneous nevi. *Nat. Genet.* **41**, 915-919 (2009).
86. Garraway, L.A. *et al.* Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma. *Nature* (2005).
87. Abel, E.V. & Aplin, A.E. FOXD3 is a mutant B-RAF-regulated inhibitor of G(1)-S progression in melanoma cells. *Cancer Res.* **70**, 2891-2900 (2010).
88. Weiss, M.B., Abel, E.V., Dadpey, N. & Aplin, A.E. FOXD3 modulates migration through direct transcriptional repression of TWIST1 in melanoma. *Mol. Cancer Res.* **12**, 1314-1323 (2014).
89. Golan, T. *et al.* Interactions of Melanoma Cells with Distal Keratinocytes Trigger Metastasis via Notch Signaling Inhibition of MITF. *Mol. Cell* (2015).
90. Cronin, J.C. *et al.* SOX10 ablation arrests cell cycle, induces senescence, and suppresses melanomagenesis. *Cancer Res.* (2013).
91. Guilford, P. *et al.* E-cadherin germline mutations in familial gastric cancer. *Nature* **392**, 402-405 (1998).
92. Hansford, S. *et al.* Hereditary Diffuse Gastric Cancer Syndrome: CDH1 Mutations and Beyond. *JAMA Oncol* **1**, 23-32 (2015).

93. Kim, H.C. *et al.* The E-cadherin gene (CDH1) variants T340A and L599V in gastric and colorectal cancer patients in Korea. *Gut* **47**, 262-267 (2000).
94. Wagner, R.Y. *et al.* Altered E-Cadherin Levels and Distribution in Melanocytes Precede Clinical Manifestations of Vitiligo. *J. Invest. Dermatol.* **135**, 1810-1819 (2015).
95. Padmanaban, V. *et al.* E-cadherin is required for metastasis in multiple models of breast cancer. *Nature* **573**, 439-444 (2019).

Figure Legends

Figure 1.

Title: Manhattan plot for the total CM meta-analysis.

Legend: $-\log_{10}$ of two-sided P-values for SNPs derived from a fixed-effects inverse variance weighted meta-analysis of logistic regression GWAS (Y-axis) plotted against SNP chromosome positions for the total meta-analysis (36,760 melanoma cases and 375,188 controls; for full details of analysis and covariates included see the **Online Methods**). The y-axis is limited to $-\log_{10}(1 \times 10^{-25})$ to truncate strong signals at loci such as *MC1R* and *ASIP*. The full plot is displayed in **Extended Data Figure 2**. To account for multiple testing, SNPs with a P-value less than 5×10^{-8} are deemed significant.

Figure 2.

Title: Overlap of loci identified by primary and secondary analyses.

Legend: Loci identified in the **total CM** meta-analysis (CM, green, **Supplementary Table 3**), the pleiotropic analysis with nevus count (CMnev, blue, **Supplementary Table 9**) and hair colour (CMpig, red, **Supplementary Table 10**), melanocyte TWAS (TWASmel, yellow, **Supplementary Table 10**), and TWAS using the expression of three skin tissues (TWAS3skin, orange, **Supplementary Table 12**).

Table 1. Loci previously identified in CM susceptibility GWAS. **CHR, BP:** hg19 positional information. **rsID:** dbSNP142 rs number. **Publications.** We also summarise **Supplementary Table 3;** **Gene** prioritises the functional target if known, followed by melanocyte or skin tissue TWAS data, or finally the closest protein coding gene; ‘Multiple’ indicates three or more genes. **GWS:** We indicate with yes (Y) or no (N) whether this locus is genome-wide significant ($P < 5 \times 10^{-8}$) in the total meta-analysis. The effect allele (**EA**) and non-effect allele (**NEA**) are listed, as are the effect allele **Frequency** in the HRC reference panel¹⁰⁷; total fixed-effects inverse-variance weighted meta-analysis of logistic regression two-sided P-value (**P_{meta}**) and Odds Ratio (**OR**) are from an additive model and are reported per-allele with respect to the EA. Reported results are for the total meta-analysis (36,760 melanoma cases and 375,188 controls; for full details of analysis and covariates included see **Online Methods**). We also indicate whether this locus is associated with other traits: **Nevi:** Pleiotropically associated with CM and nevus count (**Online Methods; Supplementary Table 9**); **Hair:** Pleiotropically associated with CM and hair colour (**Online Methods; Supplementary Table 10**). Tanning response (**Tan**) and Telomere length (**Telo**) indicates the lead SNP is associated with these traits when corrected for multiple testing (**Online Methods. Supplementary Table 5**). ^aVariant meta-analysis results are heterogeneous ($I^2 > 31\%$) and random effects estimates are presented. ^bWhile this locus overlaps the previously reported *IRF4* or *AGR3* locus, the lead variants are independent.

CHR:BP	rsID	Pub	Gene	EA/		Pmeta	OR	Nevi	Hair	Tan	Telo
				NEA	Freq						
1:150,938,571	rs8444	108	Multiple	G/A	0.645	3.89×10^{-14}	1.08	-	-	Y	-
1:226,603,635	rs2695237	27,108,109	<i>PARP1</i>	T/C	0.628	1.53×10^{-18}	1.10	Y	-	-	-
2:38,298,139	rs1800440	23,27	<i>CYP1B1</i>	T/C	0.824	6.97×10^{-15}	1.10	Y	-	Y	-
2:202,143,928	rs10931936 ^a	20	<i>CASP8</i>	T/C	0.281	2.17×10^{-8}	1.08	-	-	-	-
5:1,323,212	rs13178866 ^a	20,110,111	<i>TERT</i>	C/T	0.554	2.59×10^{-18}	0.87	-	Y	-	Y
5:33,951,693	rs16891982 ^a	20,34,111	<i>SLC45A2</i>	C/G	0.122	1.96×10^{-28}	0.51	-	Y	Y	-
6:21,163,919	rs6914598	23	<i>CDKAL1</i>	T/C	0.683	1.18×10^{-18}	0.91	-	-	Y	-
7:17,134,708	rs117132860 ^b	23,57	<i>AGR3</i>	G/A	0.981	3.83×10^{-21}	0.71	Y	-	Y	-
9:21,803,880	rs871024 ^a	18,27	<i>MTAP,</i> <i>CDKN2A</i>	C/A	0.477	2.72×10^{-23}	1.18	Y	Y	-	-
9:109,054,417	rs10739220	23,27	<i>TMEM38B</i>	C/T	0.260	1.34×10^{-18}	1.10	Y	Y	-	-
10:105,694,301	rs7902587	23,27	<i>OBFC1</i>	C/T	0.904	2.68×10^{-23}	0.86	Y	-	-	Y
11:69,380,898	rs4354713	20,23	<i>CCND1</i>	A/G	0.356	8.50×10^{-21}	1.10	-	Y	-	-
11:89,017,961	rs1126809 ^a	18	<i>TYR</i>	G/A	0.757	4.78×10^{-37}	0.83	-	Y	Y	-
11:108,175,462	rs1801516	20	<i>ATM</i>	G/A	0.856	2.22×10^{-21}	1.14	Y	-	-	-
15:28,365,618	rs12913832 ^a	19,23	<i>OCA2</i>	A/G	0.335	4.85×10^{-12}	0.88	-	Y	Y	-
16:89,986,117	rs1805007 ^a	18	<i>MC1R</i>	C/T	0.937	5.86×10^{-52}	0.57	Y	Y	Y	-
20:32,665,748	rs6059655 ^a	17,18	<i>ASIP</i>	A/G	0.061	2.52×10^{-42}	1.45	-	Y	Y	-
21:42,743,496	rs408825	20	<i>MX2</i>	C/T	0.413	1.03×10^{-32}	0.89	-	-	Y	-
22:38,545,942	rs132941	18,27,35	<i>MAFF</i>	T/C	0.549	8.80×10^{-23}	1.10	Y	-	Y	-

Table 2. Novel loci not previously identified in CM GWAS. **CHR, BP:** hg19 position. **rsID:** dbSNP142 rs number. **Gene** prioritises the functional target if known, followed by melanocyte or skin tissue TWAS data, or finally the closest protein coding gene; multiple indicates three or more genes (**Supplementary Table 3**). The effect allele (**EA**) and non-effect allele (**NEA**) are listed, as are the effect allele **Frequency** in the HRC reference panel¹⁰⁷; total fixed-effects inverse-variance weighted meta-analysis of logistic regression two-sided P-values and Odds Ratio (**OR**) are with respect to the EA. Reported results are for the total meta-analysis (36,760 melanoma cases and 375,188 controls; for full details of analysis and covariates included see **Online Methods**). **Nevi:** Associated with CM+nevus count (**Online Methods; Supplementary Table 9**); **Hair:** Associated with CM+hair colour (**Online Methods; Supplementary Table 10**). Tanning response (**Tan**) and Telomere length (**Telo**) indicate lead SNP is associated with these traits when corrected for multiple testing (**Online Methods, Supplementary Table 5**). ^aAssociated with CM by non-GWAS based approaches - *MITF*^{25,26}, *IRF4*^{27,34,35}. ^bPreviously associated pleiotropically with CM and nevus count²⁷. ^cVariant meta-analysis results are heterogeneous ($I^2 > 31\%$) and random effects estimates are presented. For rs12523094/*GPR98* while the lead SNP selected in conditional mapping is heterogenous, other SNPs in LD pass this requirement (e.g., rs12173258, $r^2_{EUR} = 0.9$, $P_{meta} = 1.09 \times 10^{-11}$, $I^2 = 29.6$). ^dPreviously associated with tanning response⁵⁷. ^eJoint CM+hair colour P-value is greater than multiple testing corrected threshold of 1.25×10^{-8} (**Supplementary Table 10**).

CHR:BP	rsID	Gene	EA/ NEA	Freq	Pmeta	OR	Nevi	Hair	Tan	Telo
1:63,727,542	rs670318	<i>FOXD3</i>	T/C	0.047	1.21×10^{-8}	0.86	-	-	Y	-
1:154,994,978	rs76798800	<i>ZBTB7B, ADAM15, GBA</i>	G/T	0.753	3.86×10^{-15}	0.92	Y	-	Y	-
1:205,181,062	rs2369633	<i>DSTYK</i>	T/C	0.083	1.24×10^{-8}	1.10	-	- ^e	Y	-
2:25,778,637	rs12473635	<i>DTNB</i>	T/C	0.776	5.17×10^{-9}	0.93	Y	-	-	-
3:70,014,091	rs149617956 ^a	<i>MITF</i>	G/A	0.998	9.00×10^{-14}	0.39	-	Y	Y	-
3:169,493,283	rs3950296 ^b	<i>TERC</i>	C/G	0.747	4.47×10^{-11}	1.08	Y	-	-	Y
5:90,262,612	rs12523094 ^c	<i>GPR98</i>	T/C	0.567	1.74×10^{-6c}	1.07	-	Y	Y	-
5:149,211,868	rs32578 ^{b,d}	<i>PPARGC1B</i>	G/A	0.658	6.58×10^{-17}	1.09	Y	-	Y	-
6:1,145,265	rs12215602 ^a	<i>IRF4</i>	G/A	0.721	7.91×10^{-9}	0.94	Y	-	Y	-
6:22,719,379	rs72834823	<i>HDGFL1</i>	T/A	0.819	1.04×10^{-12}	1.10	Y	-	Y	-
6:32,748,953	rs28986343	<i>HLA-DQB2</i>	C/T	0.952	1.61×10^{-8}	1.15	-	-	-	-
6:91,005,743	rs6908626	<i>BACH2</i>	G/T	0.844	3.92×10^{-9}	1.09	-	-	-	-
7:22,115,454	rs12539524	<i>RAPGEF5</i>	C/T	0.846	1.65×10^{-8}	0.93	-	-	-	-
7:124,396,645	rs4731207	<i>POT1</i>	G/A	0.540	2.22×10^{-15}	0.93	Y	-	-	Y
7:130,738,666	rs7778378	<i>MKLN1</i>	C/T	0.248	8.93×10^{-9}	0.93	Y	Y	-	-
8:21,951,009	rs6994183	<i>FAM160B2</i>	A/T	0.866	4.84×10^{-9}	0.92	-	-	-	-
8:72,864,240	rs13263376 ^c	<i>RP11-383H13.1, MSC</i>	G/A	0.364	2.28×10^{-8c}	0.93	Y	-	Y	-
9:12,587,153	rs10960710	<i>TYRPI</i>	G/T	0.393	3.08×10^{-12}	0.93	-	Y	Y	-
9:110,711,586	rs1339759 ^b	<i>KLF4</i>	C/G	0.666	5.61×10^{-19}	1.10	Y	-	-	-
9:134,457,580	rs3780269	<i>RAPGEF1</i>	G/A	0.691	1.92×10^{-8}	0.94	Y	-	-	-
11:16,041,305	rs7941496	<i>SOX6</i>	G/T	0.516	1.40×10^{-9}	1.06	Y	-	Y	-
11:120,195,702	rs12290699	<i>TMEM136</i>	T/C	0.745	2.20×10^{-8}	0.94	-	-	-	-
12:13,070,752	rs1056927 ^{b,e}	Multiple	A/G	0.561	2.74×10^{-9b}	0.93	Y	-	-	-
12:17,275,460	rs4237963	<i>LMO3</i>	T/A	0.207	1.27×10^{-9}	0.93	-	-	-	-
12:96,378,807	rs10859996	<i>HAL, RP11-256L6.3</i>	C/T	0.635	2.09×10^{-10}	1.07	-	-	-	-
12:116,580,291	rs113469387	<i>MED13L</i>	G/A	0.907	8.76×10^{-10}	0.91	-	Y	Y	-
13:113,535,949	rs1278768	<i>MCF2L</i>	G/C	0.488	6.33×10^{-12}	0.94	-	-	Y	-
15:33,277,710	rs117648907 ^b	<i>FNMI</i>	C/T	0.983	7.29×10^{-12}	0.80	Y	-	-	-
16:68,822,971	rs4420522	Multiple, <i>CDHI</i>	A/G	0.690	8.34×10^{-14}	0.93	Y	Y	-	-
16:82,217,153	rs2967383	<i>MPHOSPH6</i>	G/T	0.267	2.24×10^{-9}	1.06	-	-	-	Y
17:7,571,752	rs78378222	<i>TP53</i>	T/G	0.989	3.33×10^{-10}	0.76	Y	-	-	-
19:3,540,539	rs12984831 ^b	<i>MFSD12</i>	G/C	0.984	3.86×10^{-10}	0.65	Y	-	Y	-
20:62,291,767	rs143190905	<i>RETL1</i>	G/T	0.907	6.54×10^{-13}	1.15	-	-	-	Y
22:45,622,684	rs5766565	<i>KIAA0930</i>	A/G	0.647	1.44×10^{-9}	1.06	Y	Y	Y	-

22:50,722,408 rs79966207 *PLXNB2* T/C 0.849 8.68×10^{-9} 0.92 - Y - -

Table 3. Novel pleiotropic associations with CM and nevus count or hair colour. Reported CM P-values are from the total fixed-effects inverse-variance weighted meta-analysis of logistic regression two-sided P-values from GWAS representing a total of 36,760 melanoma cases and 375,188 controls (**Online Methods**). Results for the lead variants from pleiotropic loci (lead SNP reaching $P < 5 \times 10^{-8}$ following a Stouffers sample size weighted meta-analysis of CM P-values and either Nevus GWAS meta-analysis (N=65,777) or Hair Color GWAS (N=352,662) and GWAS-PW Model 3 prior probability of association (PPA) > 0.5 , **Online Methods**) distinct to those in the total CM meta-analysis (**Table 1, Table 2**). **CHR, BP:** hg19 positional information. **rsID:** dbSNP142 rs number. **Gene** prioritises genes that the variant is an eQTL for in GTEx skin datasets or otherwise is the closest protein coding gene; multiple indicates three or more genes. We report the total CM meta-analysis P (**CM P**), and the **CM+nevus** or **CM+hair** colour Stouffer's meta-analysis fixed effect P-value. Full results can be found in **Supplementary Tables 7 and 10**. ^aLocus previously reported as pleiotropically associated with CM and nevus count, but not significant for CM alone here. ^bLead SNP for Pigment (rs10434895) and nevus (rs10434895) are in LD $r^2_{EUR} = 1.0$. ^cLead SNP for Pigment (rs520015) and nevus (rs593179) are in LD $r^2_{EUR} = 0.63$. ^dSame lead SNP. ^eLead SNP for Pigment (rs62034121) and nevus (rs62034139) are in LD $r^2_{EUR} = 0.88$.

CHR:BP	rsID	Gene	CM P	CM + Nevus P	CM + Hair P
1:24787947	rs195720	<i>NIPAL3</i>	7.97×10^{-6}	-	2.24×10^{-12}
1:78450517	rs34517439	<i>DNAJB4</i>	2.23×10^{-4}	-	2.17×10^{-12}
1:214673271	rs7533482	<i>PTPN14</i>	2.79×10^{-5}	-	2.45×10^{-13}
2:135430709	rs6745983	<i>TMEM163</i>	1.69×10^{-3}	-	7.00×10^{-13}
2:214065880	rs16849932	<i>IKZF2</i>	1.46×10^{-3}	-	1.18×10^{-10}
2:240065356	rs11677464 ^a	<i>HDAC4</i>	4.00×10^{-5}	1.10×10^{-9}	-
4:37470753	rs11730662	<i>KIAA1239</i>	1.82×10^{-3}	1.19×10^{-8}	-
5:56011357	rs7714232	<i>MAP3K1</i>	6.99×10^{-4}	-	3.32×10^{-22}
6:7189567	rs75818295	<i>RREB1</i>	1.87×10^{-3}	-	8.27×10^{-10}
6:11637483	rs548304	<i>ADTRP</i>	2.67×10^{-5}	-	1.46×10^{-10}
6:15503696	rs10949304	<i>DTNBPI</i>	1.7×10^{-3}	4.96×10^{-9}	-
6:50790642	rs2857482	<i>TFAP2B</i>	3.59×10^{-5}	3.44×10^{-10}	-
6:151577739,	rs10434895,	<i>AKAP12</i>	8.17×10^{-8} ,	7.71×10^{-10}	2.07×10^{-42}
6:151577830	rs10434896 ^b		7.88×10^{-8}		
8:131138979	rs111595456	<i>ASAP1</i>	3.86×10^{-4}	2.83×10^{-10}	-
9:211762,	rs520015,	<i>CBWD1</i>	8.95×10^{-7} ,	4.13×10^{-12}	1.10×10^{-43}
9:235201	rs593179 ^{a,c}		3.78×10^{-6}		
10:5767177	rs76154345 ^a	<i>GDI2</i>	4.43×10^{-6}	7.80×10^{-11}	-
10:111889779	rs11194997	<i>MXII</i>	3.45×10^{-6}	-	2.70×10^{-11}
11:7543519	rs11041426	<i>PPFIBP2</i>	2.73×10^{-4}	-	1.66×10^{-33}
11:62203865	rs10897275	<i>AHNAK</i>	6.47×10^{-5}	-	2.47×10^{-33}
11:91616691	rs12225068	<i>FAT3</i>	3.80×10^{-5}	-	6.48×10^{-10}
13:76351286	rs474240	<i>LMO7</i>	2.53×10^{-4}	-	9.28×10^{-9}
13:114744546	rs75414584	<i>RASA3</i>	6.31×10^{-3}	-	4.62×10^{-12}
14:64390030	rs10873172 ^{a,d}	<i>SYNE2</i>	6.29×10^{-8}	5.95×10^{-13}	6.47×10^{-27}
14:69226931	rs11625064 ^d	<i>ZFP36L1</i>	3.33×10^{-6}	2.09×10^{-10}	1.83×10^{-19}
14:92795912	rs4904871	<i>SLC24A4</i>	2.06×10^{-4}	-	2.15×10^{-278}
14:103923475	rs2273699	<i>MARK3</i>	5.27×10^{-5}	-	1.21×10^{-16}
15:48400199	rs2675345	<i>SLC24A5</i>	4.92×10^{-3}	-	1.09×10^{-9}
16:54118132,	rs62034121,	<i>FTO</i>	1.16×10^{-9} ,	4.69×10^{-14}	-
16:54131939	rs62034139 ^{a,c}		4.56×10^{-9}		
16:55322732	rs12930459 ^a	<i>IRX6</i>	1.82×10^{-5}	4.89×10^{-9}	-

Table 4. Genes identified by TWAS outside of regions identified in the total CM GWAS meta-analysis. For each **gene** with a Bonferroni-corrected P-value cutoff in melanocytes ($P_{\text{TWAS}} < 3.22 \times 10^{-6}$), or skin-related tissue types ($P_{\text{TWAS}} < 5.28 \times 10^{-7}$) that does not overlap with an existing CM region we report the local peak CM variant from the total confirmed plus self-report GWAS meta-analysis, and TWAS **Z** score. Full results for all genes with a $P_{\text{TWAS}} < 1.48 \times 10^{-5}$ can be found in **Supplementary Tables 10,12**. *CBWD1* and *C9orf66* are within 1 Mb of each other and are merged into a single locus. * *RP11-676J12.7* was identified using sun-exposed skin expression data from GTEx (**Supplementary Table 12**), while all other genes were identified using melanocyte gene expression.

Gene	TWAS		Locus Peak CM Variant		
	Z	P	rsID	CHR:BP	CM P
<i>NIPAL3</i>	4.84	1.28×10^{-6}	rs2294524	1:24,770,594	2.74×10^{-7}
<i>RCAN3</i>	4.83	1.33×10^{-6}	rs2294524	1:24,770,594	2.74×10^{-7}
<i>NOTCH2</i>	4.81	1.50×10^{-6}	rs2793830	1:120,466,108	3.80×10^{-7}
<i>PTPN14</i>	-4.84	1.30×10^{-6}	rs6693492	1:214,685,978	2.68×10^{-5}
<i>CBWD1</i>	-4.81	1.51×10^{-6}	rs478882	9:205,964	1.64×10^{-6}
<i>C9orf66</i>	5.05	4.48×10^{-7}	rs478882	9:205,964	1.64×10^{-6}
<i>SYNE2</i>	5.19	2.06×10^{-7}	rs12881652	14:64,400,120	2.12×10^{-7}
<i>IRX6</i>	-4.80	1.62×10^{-6}	rs12919110	16:55,319,789	1.27×10^{-6}
<i>RP11-676J12.7*</i>	-5.55	2.79×10^{-8}	rs1703824	17:813,324	1.59×10^{-5}

Online Methods

Quality control metrics, imputation and association analysis

Data cleaning was performed using Illumina GenomeStudio/BeadStudio (v2.0.4 San Diego, CA, USA) and PLINK (v1.90b5.4)^{96,97}. Full details of the sample collections and genotyping arrays used for each GWAS are reported in the **Supplementary Methods**. Prior to imputation any SNP with either minor allele frequency (MAF) < 0.01, Hardy-Weinberg Equilibrium (HWE) P-value < 5×10^{-4} in controls or < 5×10^{-10} in cases was removed. Similarly, any individual was removed who was missing > 3% of variants, had heterozygosity values either > 0.05 or < -0.05 or 3 sd from the mean, whose genetically-predicted sex did not match their recorded sex, or who was determined to be non-European based on principal component analysis (PCA). In addition, one of any pair of individuals estimated to be related with identity by descent (IBD) $\text{pihat} > 0.15$ was removed.

The Harvard, BNMS, and 23andMe GWAS were imputed to 1000 Genomes Project phase 1 v3; for all other sets (**Supplementary Table 1**) imputation was conducted using the Michigan Imputation Server with the Haplotype Reference Consortium panel (HRC version 1) and run using Minimac3⁹⁸. Following imputation, any imputed variant with imputation quality score $r^2 < 0.5$ or MAF < 0.0001 was rejected. As rare SNPs where one allele is missing in the case or control group can lead to very large (or infinite) OR estimates, variants with an OR < 1×10^{-4} (the minimum reported by PLINK) or > 1×10^6 were also filtered. To handle variants with the same name (e.g., triplicate SNPs), variant IDs were converted to the format CHR:BP:A1A2 prior to meta-analysis.

Logistic regression under an additive model with ORs calculated on a per-allele basis was then conducted using PLINK (v1.90b5.4)^{96,97} with either geographic region (in GenoMEL Phase 1 and 2 data) or principal components as covariates to account for potential population stratification. Individual studies were checked for evidence of inflation by producing QQ plots (**Supplementary Figure 1**) and calculating the corresponding inflation factor λ and LDSC intercept (**Supplementary Table 1**).

Where individual studies have deviated from this protocol, details are included in the study description in the **Supplementary Material**. All reported tests are two-sided.

Meta-analysis and conditional-and-joint-analysis to identify independent loci

Meta-analyses of the GWAS were conducted in one stage using both inverse-variance weighted fixed effects and random effects meta-analysis⁹⁹ as implemented in PLINK v1.90b5.4^{96,97}. Meta-analyses were conducted for confirmed only cases, and in the total set including self-report sets (23andMe, Inc. and a portion of UK Biobank).

Conditional and joint analysis of summary GWAS meta-analysis data was performed using Genome-wide Complex Trait Analysis (GCTA, v1.26.0) to identify independently associated variants³³. To ensure we were only detecting completely independent SNPs the collinearity threshold (--cojo-collinear) was set to $R^2 = 0.05$. The threshold for genome-wide significance 5×10^{-8} and fixed effect meta-analysis p-values and log(OR) effect sizes were analysed.

Linkage-disequilibrium (LD) between SNPs for the conditional and joint analysis of summary data in GCTA (v1.26.0) reported in the manuscript was calculated using a reference population of 5,000 individuals selected randomly from the portion of the UK Biobank population determined to be European by PCA (LD_{EUR}). Variants were converted to best guess genotype (threshold 0.3). Best guess data were cleaned for missingness > 3%, HWE $P < 1 \times 10^{-6}$, MAF < 0.001

To limit the chance of false positive claims of novel SNP/loci, we further filtered the list of 77 conditionally independent variants (**Supplementary Table 4**) to those (i) genome-wide significant ($P < 5 \times 10^{-8}$) in single SNP and joint conditional analysis, and (ii) as recommended³⁰ where there was evidence of heterogeneity between studies ($I^2 > 31\%$) the random effect P-value also needed to be $< 5 \times 10^{-8}$. Passing variants were further checked to ensure that MAFs and effect sizes were consistent across studies and that the result was not driven by a single study (**Supplementary Figures 8-9**). The 68 retained variants were combined into 54 loci using a concatenating 1 Mb window (**Supplementary Table 3**). Regional association plots for all 54 loci were interactively plotted by LDassoc (<https://ldlink.nci.nih.gov/>)¹⁰⁰ and included as **Supplementary Materials**.

Multiple testing corrections

The primary aim of our study was to perform a GWAS meta-analysis of CM risk. For this primary analysis our significance threshold was set at $p < 5 \times 10^{-8}$. Following this primary analysis, we conducted two classes of secondary analyses: 1) joint analysis of melanoma with a risk phenotype (Nevus or Pigmentation) and 2) TWAS.

To ensure robust adjustment for multiple testing, within the joint CM-nevus and CM-pigmentation GWAS analyses we Bonferroni-corrected for each of the two risk factor phenotypes (pigmentation and nevus count), as well as accounting for the two classes of secondary analysis (joint GWAS and TWAS). The resulting significance threshold was $(5 \times 10^{-8}) / (2 \times 2) = 1.25 \times 10^{-8}$. Loci reaching this corrected threshold are indicated in bold in **Supplementary Tables 7 and 10**.

TWAS was performed on expression data from melanocytes, and then separately on the three skin tissues within GTEx (sun-exposed, not-sun-exposed, and fibroblasts) as these were the most enriched tissues in terms of enrichment for CM heritability after melanocytes (**Extended Data Figure 5A**) and are likely to be involved in CM development.

For the melanocyte TWAS analysis, we Bonferroni corrected the significance threshold by the number of tested genes in melanocytes multiplied by the 2 classes of secondary tests and further for the 2 tissue sets; $0.05 / (3878 \text{ genes} \times 2 \text{ classes} \times 2 \text{ tissue sets}) = 3.22 \times 10^{-6}$.

For the GTEx skin TWAS analysis we Bonferroni corrected for the total number of tested genes across the tissues multiplied by two classes of secondary tests and further for the 2 tissue sets; $0.05 / (8879 + 7458 + 7353 \text{ genes}) \times 2 \text{ classes} \times 2 \text{ tissue sets} = 5.28 \times 10^{-7}$.

The accuracy of p-value calculation for rare SNPs where case/control numbers are imbalanced

The non-normality of the test statistics may cause severely inflated P-values due to violation of asymptotic approximations, particularly for imbalanced case-control ratios. While we addressed this for extreme cases by filtering very rare SNPs (**Online Methods**), we also investigated whether this could be inflating the P-value of rare SNPs included in the meta-analysis by performing 5×10^8 simulations. For each simulation, we first generated genotype data for 21 studies with the same sample size as in our meta-analysis (**Supplementary Table 1**) assuming Hardy Weinberg equilibrium for variants with $MAF = 0.01$.

We then performed association testing for each study and calculated the test statistics to derive an empirical P-value of 6.4×10^{-8} when using an asymptotic P-value of 5×10^{-8} as the threshold. While imbalanced case-control ratios had minimal impact on the calculation of asymptotic p-values for SNPs with $MAF = 0.01$, as the empirical P-value was slightly larger than genome-wide significance

we further explored the results of our meta-analysis. Three of our 68 reported variants have a MAF less than 0.01: rs149617956 with MAF = 0.002, rs79356439 with MAF = 0.008 and rs3212371 with MAF = 0.003. All three variants had asymptotic p-values $< 5 \times 10^{-12}$. We performed 5×10^8 simulations for each of the variants using their MAF, and found no simulations had a nominal P-value $< 5 \times 10^{-12}$. These simulations indicate that the actual p-values for these three SNPs are less than $1/(5 \times 10^8) = 2 \times 10^{-9}$, and have reached genome-wide significance.

Joint analyses of CM and nevus count and pigmentation

Nevus GWAS meta-analysis

Using beta meta-analysis weighted by SE as implemented in PLINK 1.90b5.4, we combined the recently published nevus meta-analysis (N = 52,506)²⁷ which excluded samples with melanoma but may include a small portion of overlap with the controls used for some melanoma GWAS datasets; participants of the QSkin study with nevus count that are non-overlapping and unrelated (IBD $\pi_{\text{hat}} < 0.15$) to the QSkin melanoma case control set (N = 12,930) and the final set of participants not previously included from the Brisbane Twin Nevus Morphology study (N = 341)²⁷. The total sample size was 65,777.

Pigmentation GWAS

A GWAS for hair colour was performed on 352,662 UK Biobank samples not included in the melanoma GWAS who self-reported having either blonde, light brown, dark brown or black hair (coded as 1, 2, 3 and 4). Hair colour was then treated as a continuous variable and regressed on imputed genotype adjusting for principal components using the same approach as for the melanoma GWAS.

Joint analyses

The melanoma results were then jointly analysed first with nevus count and then with hair colour. Two approaches were taken. Firstly the total confirmed plus self-report CM GWAS meta-analysis results were combined with the separate nevus and pigmentation GWAS data using Stouffer's method (P-value weighted by per SNP sample N) as implemented in METAL (version 2011-03-25)¹⁰¹. LD calculations were performed in PLINK using a reference panel of 10,000 white British UK Biobank individuals as implemented in the FUMA platform (v1.3.5)¹⁰² was used to identify independent SNPs with $P < 5 \times 10^{-8}$; independent SNPs within 1 Mb were considered to be single loci. Secondly, the melanoma and pigmentation/nevus GWAS results were analysed using GWAS-PW (v0.21)³⁸, which estimates the posterior probability of four possible models for each genetic region: (i) association with CM only, (ii) association with the second trait only, (iii) association with both traits (pleiotropic), (iv) association with both traits, but co-located and independent (v) no association with either trait. Given that nevus count and pigmentation are believed to act directly on melanoma risk, model (iv) seemed unrealistic so we only considered models (i), (ii), (iii) and (v). For nevus count, SNPs were assigned to blocks using the recommended boundaries for GWAS-PW (<https://bitbucket.org/nygcresearch/lddetect-data>). For CM and hair colour, 50 SNP windows were used for blocks as the default LD blocks contained multiple independent hair colour loci. Following the approach taken by²⁷, any locus with a lead SNP reaching $P < 1.25 \times 10^{-8}$ for the combined CM and nevus/hair colour analysis and with a posterior probability > 0.5 that the locus is associated with both traits (model 3) to ensure that the association is not driven by a single trait was declared to be pleiotropically associated with both traits.

Analysis of pigmentation and nevi polygenic risk score across melanoma subtypes

For each subject in our study, we calculated two polygenic scores (PRS), using 276 genetic variants associated with pigmentation and 10 genetic variants associated with nevus count. Nevus count SNPs were derived from the same nevus GWAS meta-analysis used for the pleiotropic analysis (N = 65,597), with independent lead SNPs with $P < 5 \times 10^{-8}$ identified using LD calculations performed in PLINK using a reference panel of 10,000 white British UK Biobank individuals as implemented in the FUMA platform (v1.3.5)¹⁰², with the LD r^2 cut off for independence < 0.05 . Pigmentation PRS SNPs were selected from the hair colour GWAS used for the pleiotropic analysis (N= 352,662), with independent lead SNPs with $P < 5 \times 10^{-8}$ and LD calculations performed in PLINK using a reference panel of 10,000 white British UK Biobank individuals as implemented in the FUMA platform, with the LD r^2 cut off for independence < 0.025 . PRS were calculated for each subject by applying the regression coefficient (from the GWAS of pigmentation or nevus count) to the genotype dosages. We then tested whether PRS distribution differed between males and females, across age groups, and histology subtypes. In total, we performed 27 comparisons and thus any comparison with p-value less than $0.05/27$ ($=0.00186$) was declared as statistically significant.

GENESIS estimation of heritability and polygenic risk

We used GENESIS (<https://github.com/yandorazhang/GENESIS>)³² (Version 2019-06-01) to estimate the genetic architecture (number of causal SNPs and their effect size distribution) using the summary level statistics from the GWAS meta-analysis. Quantile-quantile plot comparing the p-values generated from this fitted distribution against the observed p-values suggested a three component Gaussian mixture model for the effect size distribution. Based on this estimated genetic architecture, we calculated the heritability at the observational scale and the number of SNPs reaching genome-wide significance for a given GWAS with known sample size. Similarly, GENESIS calculated the AUC for an additive polygenic risk prediction model built based on a discovery GWAS of known sample size.

UK Biobank melanoma risk phenotype GWAS

Four pigmentation GWAS were performed on UK Biobank participants not included in the melanoma GWAS (1) Ease of tanning with 367,229 UK Biobank samples who self-reported their ability to tan as either 'Get very tanned', 'Get moderately tanned', 'Get mildly or occasionally tanned' or 'Never tan, only burn' (coded as 1, 2, 3 and 4). Ease of tanning was treated as a continuous variable and regressed on imputed genotypes adjusting for principal components using the same approach as for the melanoma GWAS of UK Biobank data. (2) Skin colour with 370,260 UK Biobank samples who self-reported having either 'Very fair', 'Fair', 'Light olive', 'Dark olive', 'Brown', or 'Black' skin colour (coded as 1, 2, 3 and 4). Skin colour was treated as a continuous variable and regressed on imputed genotype adjusting for principal components using the same approach as for the melanoma GWAS of UK Biobank data. (3) Number of childhood sunburns with 320,345 UK Biobank samples who self-reported their sunburn incidents pre-sixteen years old. The data were dichotomised into none and at least one pre-sixteen sunburn incident categories (coded as 1, 2). Number of childhood sunburns was treated as a binary variable and regressed using a logistic model on imputed genotype adjusting for principal components using the same approach as for the melanoma GWAS of UK Biobank data. (4) Red hair with 120,925 UK Biobank samples who self-reported having either 'red hair' or other (coded as 1 or 2). Red hair was treated as a binary variable and regressed using a logistic model on imputed genotype adjusting for principal components using the same approach as for the melanoma GWAS of UK Biobank data.

Linkage disequilibrium (LD) score regression

As LD score regression (LDSC) is sensitive to the quality of input SNPs, GWAS or meta-analysis variants were filtered to the list of high quality HapMap SNPs provided¹⁰³. Using LD Score regression v1.0.0 genomic inflation (Lambda), intercept and SNP-heritability (h^2) were estimated. h^2 estimates were converted to the liability scale using the lifetime population prevalence for CM in Australia (0.0588)¹⁰⁴.

LD score regression of tissue-specific genes

CM heritability enrichment for SNPs around tissue-specific genes was assessed by stratified LD score regression as described previously^{28,42} and implemented in the LDSC program v1.0.0 (<https://github.com/bulik/ldsc>). Briefly, RNA-seq data for all 50 GTEx (v7) tissue types and primary melanocyte were quantified as RPKM using RNA-SeQC (v1.18)¹⁰⁵ and quantile normalized to reduce batch effect. Tissue-specific genes were defined by calculating the t-statistic of each gene for a given tissue, excluding all samples from the same tissue category. Tissue category assignment for GTEx tissue types was based on the previous publications^{28,106}, and melanocytes were defined as “skin” category together with two types of skin and transformed skin fibroblasts from the GTEx. We selected the top 1,000, 2,000, and 4,000 tissue-specific genes from the t-statistic analysis, and added 100 Kb each to the transcription start site and transcription end site to define tissue-specific genes annotation. Stratified LD score regression was then applied on a joint SNP annotation to estimate the heritability enrichment against the total CM GWAS data from the current study.

Colocalization of CM GWAS and eQTLs

We performed colocalization analyses of CM GWAS signals with eQTL signals from our melanocyte and 48 GTEx (v7) tissue eQTL datasets (note that 2 tissue types that were included for LDSC using expression data were not included here as well as in TWAS analyses due to lack of eQTL data from GTEx), using eQTL and GWAS CAusal Variants Identification in Associated Regions (eCAVIAR, v2.0, <http://genetics.cs.ucla.edu/caviar/>, <https://github.com/fhormoz/caviar>)⁴³. Consistent with the previous study, we used 50 SNPs upstream and downstream of each CM GWAS lead SNP to extract both GWAS and eQTL summary statistics to be used as the input for eCAVIAR analysis. The LD matrix was calculated using the unphased 1000 Genomes reference set. For the CLPP score calculation, we allowed a maximum number of two causal SNPs in each locus. For a given CM GWAS locus, an eGene with a CLPP score above 1% (0.01) was considered to display a positive co-localization. To avoid reporting spurious effects, we applied a conservative criterion and only reported variants displaying LD $r^2 > 0.9$ with the CM GWAS lead SNP and eQTL P-value below a Bonferroni-corrected cutoff of each dataset (0.05/number of eGenes tested for each tissue dataset).

TWAS

We performed transcriptome-wide association studies (TWAS) for the CM GWAS meta-analysis data using TWAS/FUSION (<http://gusevlab.org/projects/fusion/>) as previously described^{28,41}. TWAS was performed in three separate groups, using eQTL datasets from 1) melanocytes, 2) three skin tissues (sun-exposed, not-sun-exposed, and fibroblasts) within GTEx (V7), and 3) the rest of GTEx tissue types (a total of 45) by imputing the gene expression phenotypes for the total CM GWAS meta-analysis data. The analysis parameters were set to allow for multiple prediction models, independent reference LD, additional feature statistics and cross-validation results⁴¹. The

total CM GWAS meta-analysis summary statistics were included with no significance thresholding. For GTEx data, we downloaded the precomputed expression reference weights for GTEx gene expression (v7) RNA-seq across 48 tissue types from the TWAS/FUSION website (<http://gusevlab.org/projects/fusion/>). We computed functional weights from the primary melanocyte RNA-seq data²⁸ one gene at a time. Genes that failed quality control during the heritability check (using minimum heritability P-value 0.01) were excluded from further analyses. We restricted the *cis*-locus to 500 Kb on either side of the gene boundary.

Data Availability

Genome-wide summary statistics for the confirmed meta-analysis have been made publicly available at dbGaP (phs001868.v1.p1). Results for SNPs with a fixed or random $P < 5 \times 10^{-7}$, from the total meta-analysis are reported in **Supplementary Table 7**.

Methods References

96. Purcell, S. *et al.* PLINK: a tool set for whole-genome association and population-based linkage analyses. *Am. J. Hum. Genet.* **81**, 559-575 (2007).
97. Chang, C.C. *et al.* Second-generation PLINK: rising to the challenge of larger and richer datasets. *Gigascience* **4**, 7 (2015).
98. Das, S. *et al.* Next-generation genotype imputation service and methods. *Nat. Genet.* **48**, 1284-1287 (2016).
99. DerSimonian, R. & Laird, N. Meta-analysis in clinical trials. *Control. Clin. Trials* **7**, 177-188 (1986).
100. Machiela, M.J. & Chanock, S.J. LDassoc: an online tool for interactively exploring genome-wide association study results and prioritizing variants for functional investigation. *Bioinformatics* **34**, 887-889 (2018).
101. Willer, C.J., Li, Y. & Abecasis, G.R. METAL: Fast and efficient meta-analysis of genomewide association scans. *Bioinformatics* (2010).
102. Watanabe, K., Taskesen, E., Van Bochoven, A. & Posthuma, D. Functional mapping and annotation of genetic associations with FUMA. *Nat. Commun.* (2017).
103. Bulik-Sullivan, B.K. *et al.* LD Score regression distinguishes confounding from polygenicity in genome-wide association studies. *Nat. Genet.* **47**, 291-295 (2015).
104. Australian Institute of, H. & Welfare. Cancer in Australia: Actual incidence data from 1982 to 2013 and mortality data from 1982 to 2014 with projections to 2017. *Asia Pac. J. Clin. Oncol.* **14**, 5-15 (2018).
105. DeLuca, D.S. *et al.* RNA-SeQC: RNA-seq metrics for quality control and process optimization. *Bioinformatics* **28**, 1530-1532 (2012).
106. Finucane, H.K. *et al.* Heritability enrichment of specifically expressed genes identifies disease-relevant tissues and cell types. *Nat. Genet.* **50**, 621-629 (2018).
107. McCarthy, S. *et al.* A reference panel of 64,976 haplotypes for genotype imputation. *Nat. Genet.* **48**, 1279-1283 (2016).
108. MacGregor, S. *et al.* Two novel loci for melanoma susceptibility on chromosome bands 1q42.12 and 1q21.3. *Nat. Genet.* (2011).
109. Peña-Chilet, M. *et al.* Genetic variants in PARP1 (rs3219090) and IRF4 (rs12203592) genes associated with melanoma susceptibility in a Spanish population. *BMC Cancer* **13**(2013).
110. Law, M.H. *et al.* Meta-analysis combining new and existing data sets confirms that the TERT-CLPTM1L locus influences melanoma risk. *J. Invest. Dermatol.* **132**, 485-487 (2012).

111. Antonopoulou, K. *et al.* Updated field synopsis and systematic meta-analyses of genetic association studies in cutaneous melanoma: the MelGene database. *J. Invest. Dermatol.* **135**, 1074-1079 (2015).